A Study of Serum Paraoxonase-1 Activity in Patients with Metabolic Syndrome by Rajalakshmi, T
1 
 
A STUDY OF SERUM PARAOXONASE - 1 
ACTIVITY IN PATIENTS WITH 
METABOLIC SYNDROME 
                                                 
Dissertation Submitted for 
M.D DEGREE BRANCH - XIII 
[BIO CHEMISTRY] 
 
DEPARTMENT OF BIOCHEMISTRY 
THANJAVUR MEDICAL COLLEGE, 
THANJAVUR 
 
THE TAMILNADU DR.MGR MEDICAL UNIVERSITY, 
CHENNAI 
APRIL - 2015 
2 
 
CERTIFICATE 
 
This is to certify that dissertation titled “A STUDY OF SERUM 
PARAOXONASE–1 ACTIVITY IN PATIENTS WITH METABOLIC 
SYNDROME”is a bonafide work done by  Dr.T.RAJALAKSHMI under 
my guidance and supervision in the Department of Biochemistry, 
Thanjavur Medical College, Thanjavur during her post graduate course 
from 2012 to 2015. 
 
(Dr.K. MAHADEVAN.M.S)   (Dr. N.SASIVATHANAM M.D. D.G.O) 
    THE DEAN                                                   Professor and Head of the Department 
Thanjavur Medical College                      Department of Biochemistry 
Thanjavur-4          Thanjavur Medical College 
             Thanjavur-4  
 
  
3 
 
 
DECLARATION 
 
I, Dr.T. RAJALAKSHMI hereby solemnly declare that the 
dissertation title “A STUDY OF SERUM PARAOXONASE-1 
ACTIVITY IN PATIENTS WITH  METABOLIC SYNDROME” was 
done by me at Thanjavur  Medical College and Hospital, Thanjavur under 
the Supervision and Guidance of my Professor and Head of  the 
Department Dr.N.Sasivathanam, M.D( Bio).,DGO, This dissertation is 
submitted to Tamil Nadu Dr. M.G.R Medical University, towards partial 
fulfillment of requirement for the award of M.D. Degree  (Branch –XIII) in 
Biochemistry. 
 
 
Place: THANJAVUR 
 
Date:                T. RAJALAKSHMI 
                                                                                           
 
 
 
                            
 
4 
 
                                   GUIDE CERTIFICATE 
GUIDE: Prof.  Dr.N.SASIVATHANAM M.D., D.G.O., 
    THE PROFESSOR AND HEAD OF THE DEPARTMENT, 
     Department of Biochemistry 
     Thanjavur medical college & Hospital, 
     Thanjavur. 
 
CHIEF CO-ORDINATOR: 
 Prof.  Dr .SASIVATHANAM M.D. ,D.G.O., 
 THE  PROFESSOR AND HEAD OF THE DEPARTMENT, 
 Department of Biochemistry, 
 Thanjavur medical college & Hospital, 
 Thanjavur. 
 
 
Remark of the Guide: 
                     The work done by DR.T.RAJALAKSMI on “A STUDY OF 
SERUM PARAOXONASE - 1 ACTIVITY IN PATIENTS WITH METABOLIC 
SYNDROME’’ is under my supervision and I assure that this candidate 
will abide by the rules of the Ethical Committee. 
                                               
                                          GUIDE:     Prof.  Dr .SASIVATHANAM M.D., D.G.O., 
THE  PROFESSOR AND HOD,         
Department of Biochemistry, 
          Thanjavur medical college & Hospital, 
          Thanjavur 
 
  
                                        
 
5 
 
 
 
 
 
 
6 
 
      
                
 
7 
 
ACKNOWLEDGEMENT 
                    I am extremely grateful to Dr.K.MAHADEVAN, M.S., The 
Dean ,Thanjavur  Medical College for permitting me to do this dissertation 
at Thanjavur Medical College Hospital, Thanjavur.  
                   I am indebted greatly to my Professor and Head of the 
Department, Department of Biochemistry, Dr.N.SASIVATHANAM. 
M.D(Bio), DGO, who had inspired, encouraged and guided me in every 
step of this study.  
                  I express my sincere gratitude to Dr.S.Muthukumaran.M.D., 
HOD, Department of General Medicine, for his valuable help. 
                 I express my heartiest thanks to Dr.P.Ilango. M.D (Bio)., 
Professor of Biochemistry, Dr.K.NirmalaDevi.M.D(Bio).,Associate 
Professor of Biochemistry; and Dr.P.Josephine 
LathaM.D(Bio);Associate Professor, Department of Biochemistry, 
Thanjavur Medical College for their help and suggestions for performing 
my study.  
                I sincerely thank my Assistant Professors Dr.R.Rajeswari, 
M.D(Bio).,DD., and Dr.M.Ramadevi, M.D(Bio).,D.C.H., Department of  
Biochemistry for their support during my study. 
8 
 
              I owe my thanks to my co-post graduates for their support during 
the study.  
                I would like to acknowledge the assistance rendered by Non 
Medical assistants and the Technical staffs who helped me to perform the 
study.  
                I am grateful to all my patients and volunteers who participated 
in this study. I owe my special thanks to my family members for their 
moral support in conducting the study.  
               Above all, I dedicate my sincere thanks and prayers to the 
DIVINE FORCE which guides me throughout my life towards the best.  
  
 
 
 
 
 
 
 
 
 
 
9 
 
 
 
 
                                CONTENTS 
S.NO PARTICULARS 
 
PAGE NO 
1              INTRODUCTION 
 
1 
2      REVIEW OF LITERATURE 
 
3 
3       AIMS AND OBJECTIVES 
 
52 
4    MATERIALS AND METHODS 
 
53 
5     RESULTS AND STATISTICS 
 
95 
6              DISCUSSION 
 
103 
7              CONCLUSION 
 
108 
8 LIMITATIONS OF THE STUDY 
 
109 
9  FUTURE SCOPE OF THE STUDY 
 
110 
              ANNEXURE 
 
 
             BIBLIOGRAPHY 
 
 
                PROFORMA 
 
 
             CONSENT FORM 
 
 
 
 
10 
 
                       ABBREVIATIONS 
PON-Paraoxonase 
MDA-Malondialdehyde 
Mets-Metabolic Syndrome 
DM - Diabetes Mellitus  
FBG-Fasting Blood Glucose 
TGL-Triglycerides 
HDL - High density lipoprotein  
LDL - Low density lipoprotein  
VLDL - Very low density lipoprotein  
TNF-α - Tumor necrosis factor α 
INF α - Interferon α 
IL- 6 - Interleukin 6  
PAI - Plasminogen activator inhibitor  
CETP - Cholesterol ester transfer protein  
LPL - Lipoprotein lipase  
PDE 3 - Phosphodiesterase 3  
PKA - Protein kinase A  
HSL - Hormone sensitive lipase  
CVD - Cardiovascular disease  
VEGF - Vascular endothelial growth factors  
IRS-Insulin Receptor Substrate 
PI3 Kinase-Phosphatidyl Inosital 3 Kinase 
11 
 
MAP Kinase-Mitogen activator protein kinase 
GLUT-Glucose transporters 
FFA-Free Fatty acids 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
Background: Metabolic syndrome leads to prothrombotic & 
proinflammatory state that result in LDL oxidation which plays an important 
role in the development of Atherosclerosis. In normal individuals, High Density 
Lipoprotein inhibits the oxidation of LDL.Serum Paraoxonase-1 is an HDL 
associated enzyme capable of hydrolyzing oxidized phospholipids & various 
substrates.Thus, estimation of PON-1 activity in metabolic syndrome is 
valuable in assessing the risk for atherosclerosis and thereby predicting future 
cardiovascular complications. 
AIMS AND OBJECTIVES 
              1) To estimate the levels of serum Paraoxonase-1 in patients with 
metabolic syndrome and to compare the levels with healthy controls. 
             2) To evaluate the association of Paraoxonase -1 activity & 
malondialdehyde levels with components of metabolic syndrome. 
MATERIALS AND METHODS 
                                     PON-1 activity was estimated using the paraoxon (O,O 
diethyl-O-4 nitro phenyl phosphate) as the substrate for hydrolysis. Fasting 
Blood glucose was estimated by GOD-POD method. The serum triglycerides 
were measured by enzymatic (GPO-PAP method).For the determination of total 
cholesterol, an enzymatic (GPO-PAP) method was used.HDL was measured by 
Phosphotungstic acid method .VLDL & LDL were calculated by friedwalds 
formula.Estimation of Malondialdehyde (MDA) by Thio Barbituric Acid 
reactivity assay method. 
RESULTS 
                   The serum PON1 activity among the Study group (59.32 19 U/L) 
is significantly lower than the control group (154.84 30.71 U/L). The Serum 
Malondialdehyde values in study group (7.81  3.8 µmol/L) is significantly 
increased, than that of control group (2.8091.40). As the number of 
components of Metabolic Syndrome increases mean PON 1 Activity decreases 
& mean MDA levels increases. 
CONCLUSION 
               This study shows that there is a significant decrease in PON-1 activity 
in Metabolic Syndrome group and there is significant increase in 
Malondialdehyde .Since PON-1 is an antiatherogenic and antioxidant enzyme, 
associated with HDL, reduction in PON-1 activity in Metabolic Syndrome, may 
play an important role in causation of premature atherosclerosis. Based on the 
results obtained the present study shows that PON-1 activity may be used as a 
useful marker for early prediction of atherosclerosis in Metabolic Syndrome. 
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INTRODUCTION 
 
  Metabolic syndrome is one of the major public health concerns and 
its prevalence has increased worldwide with a subsequent predisposition to 
Coronary Artery Disease, Type II Diabetes mellitus and Stroke. It 
comprises a group of interrelated abnormalities namely Central Obesity, 
Elevated Fasting Glucose levels, Elevated blood pressure, High 
triglycerides, Reduced levels of High-Density Lipoprotein (HDL-C) .
1
  
Metabolic syndrome leads to prothrombotic & proinflammatory 
state that leads to LDL oxidation which plays an important role in the 
development of Atherosclerosis.  
In normal individuals, High Density Lipoprotein inhibits the 
oxidation of LDL.Serum Paraoxonase-1 is an HDL associated enzyme 
capable of hydrolyzing oxidized phospholipids & various substrates. 
Serum Paraoxonase is a major determinant of lipids and lipoprotein 
concentration. Genotype of PON-1 were significantly associated with a 
variation in plasma concentration of lipid level.
2
 
PON-1 prevents atherogenesis by protecting the LDL and HDL 
against peroxidation and by inhibiting the monocyte-endothelial 
interactions in the inflammatory response to the vascular endothelial cells.
3 
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Thus, estimation of PON-1 activity in metabolic syndrome is 
valuable in assessing the risk for atherosclerosis and thereby predicting 
future cardiovascular complications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
 
REVIEW OF LITERATURE 
HISTORY OF METABOLIC SYNDROME 
           In 1947, Dr. Jean Vague, the Marseilles physician, found that      
abdominal obesity predisposed to atherosclerosis, diabetes and 
cholelithiasis, but the term "metabolic syndrome" was first used in 1950 
and only in late 1970 it came into common practice. 
4
 
In 1981, Hanefield and Leonhardt used the term ‘‘Metabolic 
Syndrome’’ to describe the joint incidence of diabetes, hypertension, 
hyperlipoproteinemia, gout and obesity in combination with an increased 
incidence of cardiovascular disease, fatty liver and cholelithiasis.
5
 
In 1985, Modan proposed that Insulin Resistance or 
Hyperinsulinemia as a common pathophysiological feature for Obesity, 
Hypertension and Glucose Intolerance.
6
 
In 1988, Gerald M.Reaven, an endocrinologist from Stanford 
University, interpreted the association of diabetes, obesity, dyslipidemia 
and arterial hypertension by their pathogenic relationship with the 
peripheral Insulin-Resistance and he named the above association  as “X 
syndrome”. 7 
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          The X syndrome    was    renamed   as   “The Deadly Quartet”   by    
Kaplan in 1989.  It   was   again renamed as “Insulin Resistance 
Syndrome”  in   1992.                
             Hjerrman proposed renaming Syndrome X as "Metabolic 
Cardiovascular Syndrome" or "Atherothrombogenic Syndrome".
8
  
              The Centers for Disease Control and Prevention approved for a 
new diagnostic code, ICD-9-CM 277.7 for "Dysmetabolic Syndrome X" in 
2001. 
Synonyms for Metabolic Syndrome
6
 
 Hyperinsulinemia Syndrome /Insulin Resistance Syndrome 
 Atherothrombogenic Syndrome  
 Metabolic Cardiovascular Syndrome  
 Wohlstands syndrome (Germany) 
 Dysmetabolic Syndrome X  
 Syndrome X plus  
 Deadly quartet  
 Android Obesity Syndrome  
 Syndrome of Affluence  
 Plurimetabolic syndrome  
 GHO (Glucose intolerance/ Hypertension/Obesity syndrome) 
16 
 
 Syndrome X  
 Metabolic syndrome X  
 Reaven syndrome  
 HONDA --- Hypertension, Obesity, Non insulin dependent Diabetes 
Mellitus,Dyslipidaemia, Atherosclerotic  Cardiovascular disease 
 CHOAS (Australia)- Coronary Artery Disease, Hypertension, 
Obesity,Atherosclerosis, and Stroke. 
DEFINITIONS: 
At present, there are four sets of criteria most commonly used for 
defining the Metabolic Syndrome. 
THE METABOLIC SYNDROME-WHO CRITERIA(1998): 
10
 
 This definition must have the presence of insulin resistance(Type 2 
diabetes /IFG/IGT/other evidence of IR like euglycemic clamp) 
study),along    with    any   two of the following: 
 Central obesity :  Body mass index ≥  30 kg/m2or 
Waist: hip ratio> 0.85 for female,  > 0.90 for male. 
 Dyslipidemia: HDL ≤ 0.9 mmol/L for male, 
                         HDL ≤ 1.0 mmol/L for female   
                         TGL ≥ 1.695 mmol/L. 
 Blood pressure:  ≥ 140/90 mmHg. 
17 
 
 Microalbuminuria:  Albumin: creatinine ratio ≥ 30   mg/g   or   
urinary albumin   excretion   ratio ≥ 20 µg/min. 
EUROPEAN GROUP FOR THE STUDY OF INSULIN 
RESISTANCE (EGIR) CRITERIA (1999)  
11
 
The EGIR felt that Insulin Resistance plays a central role in 
metabolic syndrome. 
 Insulin Resistance is defined as a fasting plasma insulin value 
greater than 75th percentile. 
Plus any two of the following 
 Waist circumference :  ≥ 94(male), ≥90 (female) 
 Blood pressure: systolic ≥ 140 or diastolic ≥ 90 mmHg. 
  TGL ≥177mg/dl.  
  HDL: <39mg/dl. 
THE NATIONAL CHOLESTEROL EDUCATION PROGRAM 
(NCEP) ADULT TREATMENT PANEL III (ATP III)-2001:
12
 
       Metabolic Syndrome is present if ≥3/5 criteria are fulfilled. 
 Blood pressure: systolic ≥ 130 or diastolic ≥ 85 mmHg. 
 Fasting Triglycerides≥150mg/dl. 
18 
 
 Waist circumference: ≥ 40 inches or ≥ 102 cms for male, ≥ 35 inches 
or≥ 88 cms for female. 
 Fasting plasma glucose:  ≥ 110mg/dl. 
 Fasting HDL: < 50 mg/dl for female and   < 40 mg/dl for male. 
The NCEP ATP III definition is most widely used criteria of 
MetS because of its simple in application & results are readily 
available. 
INTERNATIONAL DIABETES FOUNDATION (IDF)–CRITERIA 
(2005): 
13
 
Central obesity and any two of the following: 
 Known case of type II Diabetes Mellitus or Elevated Fasting 
Plasma Glucose (FPG): ≥ 100 mg/dl. 
 Fasting Triglycerides ≥ 150mg/dl or on specific medication. 
 HDL cholesterol < 50 mg/dl and < 40 mg/dl for women and men 
respectively. 
 Blood pressure >85 mmHg diastolic or>130 mmHg systolic or a 
known case of hypertension. 
Waist circumference with geography – specific values for defining Central 
obesity. 
19 
 
Central Adiposity by  IDFCriteria: 
11
 
Men Women Ethnicity 
≥85cm ≥90cm 
Japanese. 
 
≥90cm ≥80cm 
Central American, Chinese &South Asian. 
 
≥94cm ≥80cm 
Middle  Eastern,  Eastern, 
Europid&  Sub-Saharan  African 
 
MODIFIED NCEP ATPIII-CRITERIA FOR THE METABOLIC 
SYNDROME(2005):
14
 
The important changes in this criteria include: 
(i)The ethnic difference in central obesity. 
   i.e., 90 cms in Asian men & 80 cms in Asian women. 
(ii) Impaired Fasting Glucose ≥ 100mg/dl  
(iii) If patients are receiving drug treatment for individual components, 
those components are counted as abnormal. 
By making these differences the predictive ability to diagnose MS has 
become highest with modified NCEP-ATP III. 
 Metabolic Syndrome is present if three or more of the following five 
criteria are met with 
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 Waist circumference :  
African Americans, whites, Latin Americans. 
                         Male- ≥ 40 inches or   ≥ 102 cm ,  
                         Female - ≥ 35 inches or   ≥ 88 cm   
        Asians- 
                        Male- ≥ 35 inches or   ≥ 90 cm,  
                        Female - ≥ 32 inches or   ≥ 80 cm   
 Blood pressure: systolic ≥ 130 or diastolic ≥ 85 mmHg or on 
treatment. 
 Fasting triglyceride (TG) level: Triglycerides≥150mg/dl or on 
treatment. 
 Fasting plasma glucose:  ≥ 100mg/dl or on treatment. 
 Fasting high-density lipoprotein (HDL) cholesterol level: <50mg/dl 
(female) and < 40 mg/dl   (male) or on treatment. 
EPIDEMIOLOGY 
 One-quarter of the world's adult population has Metabolic 
Syndrome. 
  In Developed countries like the United States, Metabolic Syndrome 
affects 47 million Americans.
15
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 1988-1994, nearly 24% of U.S. adults aged 20 years or older have 
MetS. , 27% in 1999-2000 and 34% in 2010.
 7
 
 The prevalence in 7 European countries was approximately 23%. 
  It was estimated that 20%–25% of South Asians have developed 
MS.
17
 
 In southern India, the prevalence of MetS was 26.9% in males and 
18.4% in females. .
18
 
 The incidence of Metabolic syndrome progressively rises with 
increasing age, reaching a peak between 60 and 69 years and the 
prevalence increasing from 10% in the 30–39-year age group to 45% 
in the 60–69-year age group. 
RISK FACTORS OF METS
19
 
 Obesity 
 Diet 
 Sedentary life style  
 Aging 
 Stress  
 Smoking 
 Disrupted chronobiology / sleep 
 Excessive alcohol consumption  
 Race. 
 History of diabetes 
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OBESITY  
        Metabolic Syndrome increases with increasing levels of BMI in men 
and women. 
Two major types of Fat distribution in Metabolic Syndrome 
 Apple shaped obesity or Android pattern has more visceral fat and 
has got increased truncal abdominal fat is more dangerous and it is 
common among men. 
 Gynoid or excess gluteofemoral fat or Pear shaped fat 20 
SEDENTARY LIFE STYLE  
  Regular and sustained physical activity positively decreases the 
individual components of the metabolic syndrome. 
 Physical inactivity may be an important modifiable risk factor in the 
etiology of the metabolic syndrome. 
11
 
DIET  
    Total energy intake and diet composition influences insulin sensitivity. 
 High mono unsaturated fat improves insulin sensitivity compared 
with high-saturated-fat diet.If the total fat intake is 38%, beneficial 
effect of monounsaturated fat is lost. 
23 
 
 High-carbohydrate diet worsens fibrinolysis which leads to increase 
of PAI-1 in blood. 
 Alcohol intake of about >30g/day increases both Bp & TG levels. 
 The blood pressure is elevated by increased intake of sodium 
chloride.
21
 
 
AGEING 
 The increase in proinflammatory cytokines is associated with 
ageing. 
 Aging leads to loss of mitochondrial function in various tissues like 
skeletal muscle leads to generation of Reactive Oxygen Species and 
oxidative damage of macromolecules. 
22
 
 STRESS  
 Stress leads alteration in Autonomic Nervous System and 
neuroendocrine systems. 
 The neuroendocrine responses from the hypothalamic-pituitary-
adrenal axis and the sympathetic nervous system stimulate the 
stress-related cortisol secretion, this contributes to the development 
of dyslipidemia, abdominal obesity, hypertension and insulin 
resistance and further leads to CVD 
23
 
 
24 
 
SMOKING 
 It reduces insulin sensitivity 
 It increases sympathetic stimulation & increases cortisol level. 
 It decreases testosterone levels in men which lead to increase in 
visceral fat. 
DISRUPTED CHRONOBIOLOGY/SLEEP 
 Disruption in circadian rhythm due to alteration in melatonin levels 
leads to MetS. 
 Healthy individuals restricted to 4 hours of sleep for six consecutive 
nights causes impaired glucose tolerance and reduced insulin 
responsiveness following a glucose challenge. 
23
 
EXCESSIVE ALCOHOL CONSUMPTION 
 Protective and detrimental associations have been reported between 
alcohol consumption and the metabolic syndrome.  
 A minimal amount of alcohol consumption has protective effect on 
prevalence of the metabolic syndrome compared with nondrinking 
individuals.  
 The prevalence of the metabolic syndrome increases with lifetime 
drinking intensity (total drinks/drinking days over lifetime). 
24
 
RACE 
 Asians and Hispanics have greater risk of metabolic syndrome.  24 
25 
 
FAMILY HISTORY OF DIABETES  
 Family history of type 2 Diabetes mellitus or a history of diabetes 
mellitus during pregnancy (gestational diabetes) leads to Metabolic 
Syndrome. 
OTHER DISEASES  
Polycystic Ovary Syndrome and Nonalcoholic Fatty liver disease 
that affects a woman's hormones and reproductive system also raises the 
risk of metabolic syndrome.
25
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ETIOPATHOGENESIS 
The most accepted Pathophysiology of the metabolic syndrome is 
insulin resistance. 
Mechanism of Action of insulin 
Insulin receptor is a heterotetramer, comprising two α and two β 
subunits. When Insulin binds to this α subunits, it induces a conformational 
changes in the receptor, resulting in the activation or phosphorylation of 
tyrosine kinase, which is present in the intracellular part of β subunits.In 
addition to phosphorylating itself, insulin receptor catalyzes the tyrosine 
phosphorylation of various intracellular proteins like Shc, IRS family.
26
 
IRS causes activation of PI3K which leads to activation of the 3-
phosphoinositide-dependent protein kinase-1 and Akt kinase which leads 
to metabolic effects of insulin through translocation of GLUT-4 to the cell 
surface, uptake of Glucose, Synthesis of Glycogen, Lipids & Protein.Akt 
also activates eNOS in vascular endothelial cells leads to vasodilatation 
and increased delivery of insulin and glucose to tissues. 
Shc protein causes activation of Growth Factor Receptor Bound 
Protein  which leads to MAP kinase pathway activation through SOS, Ras, 
Raf, Mitogen activated ERK (extracellular regulated kinase) - MEK. This 
MAP kinase pathway causes endothelin-1 (ET-1) production; expression of 
27 
 
the vascular cell adhesion molecules VCAM-1 and E-selectin, leading to 
more endothelial-leukocyte interactions, growth and proliferation of 
vascular smooth muscle cells.
27
 
INSULIN RESISTANCE  
Insulin resistance is defined as a defect in insulin action which is 
necessary to maintain euglycaemia or It is defined as a decreased 
biological response to the normal concentration of circulating insulin.
26 
In Insulin Resistance, MAP kinase pathway is not affected but the 
PI3K-Akt pathway is affected. Thus, insulin resistance leads to vascular 
abnormalities which predispose to atherosclerosis.
27
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  PATHOPHYSIOLOGY OF METABOLIC SYNDROME 
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DYSLIPIDEMIA 
   Excessive release of free fatty acids from adipose tissue into 
plasma leads to impaired insulin-mediated glucose uptake in muscle. 
Increased level of circulating glucose increases pancreatic insulin secretion 
resulting in hyperinsulinemia. 
 In the liver, FFAs leads to increased synthesis of TGs. FFAs also 
stabilizes and increases apoB, which leads to increased VLDL 
production.Metabolism of  VLDL causes increased LDL ,which promotes 
atheroma formation. 
28
 
The Cholesterol Ester Transport Protein transfers TGL in VLDL to 
HDL in exchange of cholesteryl esters.The TG-enriched HDL is rapidly 
cleared by hepatic lipase which leads to decreased plasma HDL level. 
11
 
            In skeletal muscle, sudden raise in FFA leads to increased DAG 
and long chain fatty acyl COA formation causes activation of protein 
kinase, which phosphorylates serine/threonine sites of insulin receptor 
substrate-1, leading to inability of insulin to activate downstream events.
27 
  The defective mitochondrial function and excessive intracellular 
accumulation of fatty acids leads to increase in the production of Reactive 
Oxygen Species, causes activation of the proinflammatory Nuclear Factor 
Kappa B pathway, thereby increasing insulin resistance.
29
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CENTRAL OBESITY 
  Central obesity is more metabolically active then peripheral fat. 
Waist circumference has to be routinely measured to assess individuals for 
increased risk for Insulin Resistance related CardioVascular Disease.  
 Visceral fat releases their metabolic products directly into portal 
circulation, which carries blood straight to the liver.
30
 Therefore free fatty 
acids are poured into the liver. Free fatty acids also accumulate in the 
pancreas, heart and other organs. This leads to organ dysfunction, 
producing impaired regulation of insulin, blood sugar and cholesterol as 
well as abnormal heart functions. This is known as Lipotoxicity. 
 Adipose tissue produces several inflammatory cytokines 
(adipokines) like Tumor Necrosis Factor α and interleukin-6 and these are 
proinflammatory and contribute to insulin resistance and vascular 
dysfunction.
31
 But, Adiponectin is a protective adipokine that increases 
insulin sensitivity in the liver, skeletal muscle glucose uptake and fatty acid 
oxidation, decreases hepatic glucose production. 
30
 
HYPERTENSION  
            Insulin causes vasodilatation, so, in insulin resistance vasodilatory 
effect is lost but sodium resorption function is preserved.
11
Fatty acids 
themselves can cause  vasoconstriction. 
31 
 
Hyperinsulinaemia leads to increased sympathetic nervous system 
activity and thus contribute to the development of hypertension. 
PROINFLAMMATORY STATE  
    Adipocyte-generated inflammatory cytokines correlates well with 
insulin resistance. The Circulating signal molecules from fat includes 
FFAs, Adiponectin, IL-6 ( IL-6 increases CRP production particulary in 
liver), Resistin, Leptin and TNF-α.31In Metabolic Syndrome, the 
inflammatory cytokines causes Insulin Resistance.     
PROTHROMBOTIC STATE  
Increased plasma Plasminogen Activator Inhibitor -1, Thrombin-
Activatable Fibrinolysis Inhibitor-1 and Fibrinogen are associated with 
metabolic syndrome.
32
 Fibrinogen and CRP , rises in response to a high-
cytokine state. Thus, proinflammatory and prothrombotic states are 
metabolically interconnected.   
Triglycerides have proatherogenic effects by promoting a 
procoagulant state due to enhanced Factor VII activity 
33
 
TPA converts plasminogen to plasmin which acts on fibrin causing 
clot dissolution; this is inhibited by plasminogen activator inhibitor.PAI 
increases with increase in BMI, LDL, and Systolic & Diastolic BP. 
33
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COMPLICATIONS OF METABOLIC SYNDROME 
CARDIOVASCULAR DISEASE 
           The mechanisms of cardiac dysfunction in the MetS are lipid 
accumulation, increased fibrosis and stiffness, altered substrate utilization, 
abnormal autophagy, altered calcium homeostasis, mitochondrial 
dysfunction  increased oxidative stress, increased fatty acid oxidation and 
enhanced NADPH oxidase activity.
34
 
              The prothrombotic and proinflammatory states in Metabolic 
Syndrome lead to cardiovascular disease.
35
 
TYPE 2 DIABETES MELLITUS 
  Increased NEFA leads to increased utilization of NEFA as energy 
source for muscle leads to increased acetyl CoA & citrate which inhibit 
PFK1 leads to decreased glucose metabolism & Defects in insulin action 
leads to impaired glucose tolerance & Type 2 diabetes.
36
 
NON ALCOHOLIC FATTY LIVER DISEASE 
 Increased FFA acid levels in Metabolic Syndrome leads to increased 
esterification of FFA &increased triglyceride synthesis & 
accumulation of triglycerides leads to steatohepatitis. 
33 
 
  In Mets, Non- alcoholic fatty liver disease (NAFLD) is more 
common which leads to non-alcoholic steatohepatitis (NASH), the 
inflammatory form of liver steatosis.  
 As the prevalence of overweight/obesity and the metabolic 
syndrome increases, NASH may become one of the common causes 
of end-stage liver disease and hepatocellular carcinoma.
11
 
HYPER URICEMIA 
 Uric acid production is linked to glycolysis which is controlled by 
insulin.  
 Insulin inhibits the activity of glyceraldehyde-3-phosphate 
dehydrogenase,leads to conversion of glyceraldehyde-3-phosphate to 
Ribose-5-phosphate which in turn converts to Phospho ribosyl pyro 
phosphate leads to increased uric acid production.
37
 
CHRONIC KIDNEY DISEASE 
IR promotes kidney disease by mechanisms such as 
 Activation of the sympathetic nervous system, sodium retention, 
decreased Na+, K+-ATPase activity, and increased GFR.  
 Endoplasmic reticulum (ER) stress seems to be the factor-linking 
inflammation and IR at the molecular level. 
34 
 
  The suppression of insulin signalling via phosphorylation of the 
insulin receptor substrate (IRS-1) due to activation of c-Jun N-
terminal kinase (JNK) plays an important role .  
 Renal ER stress is associated with alteration of nephrin N-
glycosylation in podocytes, which is the underlying factor in the 
pathogenesis of proteinuria, leads to chronic kidney injury with 
tubulointerstitial damage. 
 IR and inflammatory cytokine release leads to basement membrane 
thickening, glomerular mesangial expansion, podocytopathy, and the 
loss of slit pore diaphragm integrity leading to glomerulosclerosis 
and tubulointerstitial injury. 
38
 
 Metabolically overloaded FFA in PTECs causes increased 
expression of proinflammatory cytokines, such as TNFα & MCP1 
and, and lead to epithelial-mesenchymal transition. 
 High triglyceride levels is as such a risk factor for proteinuria 
development. 
         Hypertension and hyperinsulinemia are individual risk factors for 
MicroAlbuminuria and subsequent development of Chronic Kidney 
Disease.Hyperinsulinemia itself is a risk factor for chronic kidney disease. 
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POLYCYSTIC OVARY SYNDROME 
 Hyperinsulinemia increases IGFs in the liver and increases the 
production of androgens in the ovaries. 
 The direct effect of insulin and IGF-1 causes increased 17-
hydroxylase activity in the ovaries, causing an excessive production 
of androgens, particularly Testosterone and its precursor, 17-
hydroxyprogesterone (17-OHP). 
  IGF-1 prevents the conversion of Testosterone into Estrogens by 
inhibiting the enzyme Aromatase. 
  Insulin potentializes the action of LH in the ovaries. 
  Hyperinsulinemia decreases the hepatic production of SHBG, the 
protein that carries the sex hormone, and of IGFBP-1, the protein 
that carries IGF-1, thus contributing to a broader action of free 
testosterone (FT) and IGF-1, respectively in target-cells.
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 The inappropriate secretion of gonadotropins is associated to the 
PCOS. The increased production of gonadotropins is related to 
increased activity of GnRH pulse generator and to pituitary response 
to GnRH leads to increased LH secretion than FSH. 
 Increased LH leads to increased stimulation of stroma & theca cells 
to produce increase ovarian androgen secretion.  
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 Decreased FSH leads to decreased follicular maturation which leads 
to chronic anovulation 
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 PCOS is highly associated with the metabolic syndrome, with 
prevalence between 40 and 50%. Women with PCOS are 2–4 times 
more likely to have the metabolic syndrome than are women without 
PCOS. 
OBSTRUCTIVE SLEEP APNOEA (OSA) 
In metabolic syndrome ,there is altered hypothalamo-pitutary 
adrenal axis ,decreased Ghrelin,decreased Adiponectin & increased Leptin 
with Leptin resistance all these factors leads to OSA. 
OSA is commonly associated with Insulin Resistance, Obesity, 
Hypertension, increased circulating Cytokines, IGT.
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RELATIONSHIP BETWEEN METABOLIC SYNDROME, 
OXIDATIVE STRESS, INFLAMMATION, ATHEROSCLEROSIS 
&CARDIO VASCULAR DISEASE. 
The metabolic syndrome is associated with a higher fraction of 
oxidized LDL which exerts several biological effects which contribute to 
the initiation & progression of the atherosclerotic process.
42
 
  MetS increases TNF-α which activates and induces expression of 
specific adhesion molecules like VCAM, ICAM, and E-SELECTIN etc on 
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the endothelial cells. It also influences the behavior of circulating 
monocytes, increasing its adhesion to the endothelium. Monocytes adhere 
and penetrate in response to chemotactic factors like MCP-1 which is up 
regulated in MetS. The extracellular lipid begins to accumulate in intima 
which is often associated with proteoglycans of extra cellular matrix. 
Sequestration within the intima separates lipoproteins from plasma 
antioxidants and favours oxidative modification.
43,44
          
    The accumulation of oxidized LDL, which activates the subsets of 
smooth muscle cells and macrophages leads to gelatinase production and 
upstream localization of a vulnerable plaque phenotype. 
33
 
 Dyslipidemia in metabolic syndrome (↓ HDL & ↑ TGL) reduces 
reverse cholesterol transport and increases the formation of small dense 
LDL, which is more prone for oxidation. Small dense LDL enters the 
arterial intima more easily and binds more readily to the proteoglycans, 
through specific sequence of apoB, than the larger fraction. Binding of 
LDL in the arterial intima increases the dwelling time, and provides 
opportunity for oxidation of LDL lipids.
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            The LDL oxidation is a free radical driven chain reaction that is 
initiated by the free radical, attacking the double bond associated with 
PUFA
30
.This process starts when  a hydrogen atom is removed from a 
methylene group (-CH2-)in an unsaturated fatty acid by the free 
radical(OH•). This leaves a fatty acid as a radical itself, and the most likely 
outcome of this is that, it will react with molecular oxygen in the cell 
membrane to form a peroxyl radical.
34 
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MECHANISM OF LIPID PEROXIDE FORMATION 
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Radical damage to unsaturated fatty acids in cell membranes& 
plasma lipoproteins lead to the formation of lipid peroxides, then highly 
reactive dialdehydes that can modify protein& nucleic acid bases. The 
dialdehydes formed from lipid peroxides can be measured by reaction with 
thiobarbituric acid.
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R-CH2-CH=CH-CH2–CH2-COOH (FATTY ACID) + OH
•
 →  
R-C
•
H-CH=CH-CH3-CH2-CH2-COOH(FATTYACID RADICAL)+ H2O  
R-C
•
H-CH=CH-CH2-CH2-COOH + O2 →  
R-C(OO
•
)H-CH=CH-CH2-CH2-COOH  
PEROXYLRADICAL 
 R-C(OO•)H-CH=CH-CH2-CH2-COOH + R-CH2-CH=CH-CH2–CH2-COOH  
                                                                   
 R-C(OOH)-CH=CH-CH2-CH2-COOH +  R-C
•
H-CH=CH-CH2-CH2-COOH                                            
                            
This radical can then react with another fatty acid resulting in 
formation of lipid peroxide molecule (lipid .OOH) and fatty acid radical.
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This chain of reaction results in generation of intermediate compounds like 
malondialdehyde and 4 hydroxynonenol.
47
 These compounds then bind to 
apo B100, of LDL giving it an increased negative net charge, and 
FATTY ACID 
FATTY ACID 
RADICAL 
FATTY ACID RADICAL LIPID PEROXIDE 
PEROXYL RADICAL 
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rendering it unrecognizable by native LDL receptors but facilitate 
recognition and uptake by scavenger receptors. RBC’s   from disrupted   
microvessels causes deposition of heme  in the extracellular space ,acts as a 
source of iron which catalyse the  oxidation reaction by Fenton reaction .
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                     Lipid-OOH + Fe
2+
 → Lipid O• +OH- + Fe3+ 
Fe2+ reacts with the lipid peroxides by splitting the oxygen-oxygen
 
(o-o)bond to form a hydroxide ion and an alkoxyl radical (R-O•) 
            Monocyte derived macrophages, endocytose OxLDL via multiple 
receptors, including both class A and class B scavenger receptors (the 
expression of which is increased in Mets), lectin like oxidized LDL 
receptor -1 and lipoprotein lipase .Uptake of  lipid in excess leads to 
formation of macrophage foam cells laden in cholesterol esters. In addition 
foam cells can develop similarly from vascular smooth muscle cells by 
uptake of OxLDL via classA and classB scavenger receptors .
49 
             Oxidised LDL has several  pro atherogenic properties including, 
the rapid uptake by macropages to form  foam cells, chemoattraction for 
circulating monocytes, promotion of the differentiation of circulating 
monocytes into tissue macrophages, and inhibition of the mobility of 
resident macrophages. It is also cytotoxic to several types of cells and 
immunogenic.
50
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            Macrophage foam cells, leucocytes and resident vascular wall cells 
can secrete inflammatory cytokines and growth factors (TNFα,IL-1,MCP-
1, PDGF,FGF,TGF,etc) that amplify leucocyte recruitment and causes 
smooth muscle cell migration and proliferation.  Thus conversion of fatty 
streak to fibrous plaque occurs by accumulating vascular smooth muscle 
cells and accumulating a complex extracellular matrix that consists of 
proteoglycans, collagen and elastin
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MALONDIALDEHYDE 
 Malondialdehyde is an organic compound with the molecular 
formula CH2 (CHO)2. 
 Malondialdehyde mainly exists in the enol form 
CH2(CHO)2 → HOCH=CH-CHO 
 In water, the trans-isomer predominates, but in organic solvents, the 
cis-isomer is present. 
  Malondialdehyde is a highly reactive compound. 
 It is not typically observed in pure form. 
 Malondialdehyde is generated from reactive oxygen species (ROS), 
and as such is assayed in vivo as a bio-marker of oxidative stress 
 Reactive oxygen species degrade polyunsaturated lipids, forming 
malondialdehyde.
34
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  It is a reactive electrophile species which causes toxic stress in the 
cells 
  It forms covalent protein adducts known as advanced lipoxidation 
end-products. 
 Malondialdehyde forms DNA adducts by reacting with 
deoxyadenosine and deoxyguanosine in DNA, the primary one M1G 
is mutagenic. The  arginine residues in guanidine condenses with 
malondialdehyde to give 2-aminopyrimidines.
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 Human aldehyde dehydrogenase1A1 is capable of oxidizing 
malondialdehyde. 
MALONDIALDEHYDE IN METABOLIC SYNDROME 
           Malondialdehyde can be formed during lipid peroxidation of PUFA, 
by the action of human platelet thromboxane synthetase on prostaglandins 
PGH2, PGH3, PGG2, and  by action of polyamine oxidase and amine 
oxidase on spermine. Increased triglycerides &LDL-c, decreased HDL are 
the effective factors in the development of oxidative damage in metabolic 
syndrome.
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 Hypertrophic adipocytes secrete cytokines (IL-6, TNF-α) and 
monocyte chemoattractants (MCP-1) and are characterized by 
macrophage infiltration generating global proinflammatory profile. 
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Additionally, macrophage activation leads to NADPH oxidase 
overexpression and activation, implicated in ROS production. These 
ROS can oxidize the cell membrane lipids breaking their molecules 
with consequent increase in their plasma by-products.  
 Visceral ectopic fat deposition coexists with hypertriglyceridemia 
promoting intracellular lipotoxicity, especially in hepatocytes and 
muscle cells . In hepatocytes, increased fatty acids supply does not 
essentially result in activation of β-oxidation. Hepatocyte 
accumulation of esterified fatty acids constitutes a stressful stimulus 
that result in mitochondrial dysfunction with increased ROS 
production. 
 LDL is the lipoprotein most vulnerable to oxidation so, in metabolic 
syndrome there is increased oxidative stress. 
 Antioxidant activity of HDL activity also decreased in metabolic 
syndrome. 
 Hyperglycemia-induced oxidative stress is characterized by the 
presence of advanced glycation end-products (AGEs) . AGEs can 
oxidize lipids in cell membranes leading them to instability and 
consequent degradation to LPO by-products 
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 Hyperglycemia in metabolic syndrome is the main source of free 
radicals.Glucose in its enediol  form in a transition metal dependent 
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reaction  oxidized to enediol radical anion that is converted into 
ketoaldehyde & superoxide radical . 
 Hyperglycemia also promotes lipid peroxidation of LDL by 
superoxide dependent pathway resulting in the generation of free 
radicals.
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 Nitric oxide helps in maintenance of vascular homeostasis. It also 
decreases platelet and leukocyte adhesion to endothelial cells  and 
regulates vascular tone .Patients with hypertension have low levels 
of NO leads to increased oxidative stress and  free radical formation, 
augmented platelet  adhesion and aggregation, and a change in the 
arachidonic acid cascade metabolism, all these leading to the 
acceleration of the atherosclerotic process.
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 In Metabolic syndrome there is increased generation of 
inflammatory cytokines which also leads to generation of free 
radicals  
All these mechanisms lead to increased oxidative stress & increased 
generation of free radicals & malondialdehyde in metabolic syndrome. 
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ATTENUATION OF ATHEROSCLEROSIS: 
LDL can be protected from oxidation by antioxidants, which can act 
directly on the LDL and indirectly on the cellular oxidative machinery, and 
by HDL associated enzyme, Paraoxonase which converts OxLDL to a non 
atherogenic particle. The ability of HDL to inhibit oxidation of LDL and 
promote macrophage cholesterol efflux is through the action of several of 
its proteins, particularly Paraoxonase – 1.57 
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MECHANISM FOR ATHEROSCLEROSIS DEVELOPMENT AND 
THE ROLES OF PON1 AND PON2 AGAINST 
ATHEROSCLEROSIS. 
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PON-1 IN METABOLIC SYNDROME: 
PON-1 is the component of HDL, which is responsible for the 
antiatherogenic properties of HDL which can protect against LDL 
oxidation 
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 In Mets, there is increase in number& size of adipose tissue cells 
.When engorged with fat; adipocytes release leptin, resistin, 
cytokines & TNF-α. 
 TNF-α inhibit LCAT expression & activity which leads to alteration 
in subfraction of HDL thus it leads to decrease in Paroxonase 
activity. 
 TNF-α decreases ATP binding cassette protein & decreases ABC-
G1&A1 expression. 
 TNF-α also decreases apo-A1& apo-AIV expression all these leads 
to decline in HDL levels which is associated with decline in 
Paraoxonase activity 
 Leptin exerts atherogenic property & generates free radicals. 
 Leptin directly inhibits paraoxonase levels. 
  Increase in Leptin leads to binding of leptin hydrophobic peptide to 
HDL & inhibit binding of paraoxonase to HDL. 
  Leptin increases serum Amyloid -A protein which leads to 
replacement of ApoA1 in HDL.. 
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 Leptin enhances oxidative stress through generation of ROS & 
stimulates the secretion of inflammatory cytokines& other acute 
phase proteins.
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 This Inflammatory cytokines and acute phase proteins causes 
reduced PON-1 enzyme activity. 
  Apo A1 & Clustrein  are necessary for Paroxonase-1 stability & its 
optimal activity.
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 Paraoxonase is a lipid dependent enzyme.  Conformation of 
paraoxonase within hydrophobic environment is essential for its 
activity. 
 Phospholipids especially those with long chain fatty acid stabilize 
PON enzyme& require for binding of PON at the lipoprotein 
surface. 
 Lipid composition or products of lipid peroxidation modulate the 
structural organization & physio chemical properties of lipoproteins. 
It also alters percentage content of TG/protein & Cholesterol/protein 
which affects PON1 activity. 
Lipid peroxidation products, Oxidized LDL, oxidized palmitoyl or 
arachidonyl phosphatidyl choline& oxidized cholesterol arachidonate act 
as inactivators of enzyme activity.
60 
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 PARAOXONASE: 
 Paraoxonase (PON) is an aryl dialkyl phosphatase (E.C 3.1.8.1). It is 
a multifunctional antioxidant enzyme, which can protect against 
LDL oxidation.
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 It is a calcium dependant esterase that is known to catalyze 
hydrolysis of various substrates including organophosphates and aryl 
esters like phenyl acetate and carbamates.
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 Its has a ability to hydrolyze paraoxon, a metabolite of insecticide 
parathion.
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 Three forms of Paraoxonase enzymes are synthesised by liver and 
are 60-65% similar to each other at amino acid level
63
. 
 PON gene family consists  of three  related genes in the order of 
PON-1, PON-3 and PON-2, located on long arm of chromosome 7Q 
21.3 with 70% identity in nucleotide sequences.
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 PON- 1, PON-2 and PON-3 have 9 exons.  
 PON-2 gene is the oldest member of gene family. 
 PON-1 mRNA is primarily expressed in liver and PON-3 mRNA 
primarily in liver and also in kidney. 
 PON-2 mRNA is expressed in tissues like kidneys, liver, lungs, 
small intestine, placenta, spleen, stomach, testes and cells of arterial 
wall. 
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 PON-1 and PON-2 have similar function in human. 
 PON-1 and PON-3 reside on circulating HDL-cholesterol but PON-2 
is not associated with lipoproteins.
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PARAOXONASE 1: 
 PON-1 is a protein of 354 amino acids with molecular mass of 45 
kDa and it is synthesised mainly by the liver.
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 PON-1 in serum is exclusively located on HDL in human, which is 
responsible for the antiatherogenic properties of HDL and prevents 
LDL oxidation.
66
 
   PON-1 can bind reversibly with organophosphates and hydrolyze it 
and thus form main means of protection of nervous system against 
the neurotoxicity of organophosphates.
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 PON-1 increases  the hydrolytic breakdown of lipid hydroperoxides 
formed on phosphatidyl choline and cholesteryl esters, and also 
protects HDL from oxidation and increases its ability to induce 
macrophage cholesterol efflux.
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 PON-1 has 2 calcium binding sites, one important for catalytic 
activity, while other one for stability of enzyme. 
 Presence of calcium is required for enzymatic activity and the usage 
of EDTA destroys PON-1’s activity and stability69 
 It is shown that many amino acid residues of 
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    - Glutamine, Tryptophan, Aspartate, Histidine, Tryptophan are 
important for organophosphates and aryl esterase activities. 
 In addition, important amino acid residues of PON-1 are 3 cysteine 
residues at position 42, 284 and 353. 
 C284 – is free while C42 and C353 form disulphide bonds. 
 C 42 and C353 are important for secretion and catalytic activity of 
PON 1. Exchange of C42 and C 353   with alanine results in inactivation 
and decrease in secretion of enzyme. 
 It is assumed that C284  located  in close proximity to the active 
center of the enzyme is responsible for orientation or binding of 
substrate.
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LOCATION: 
 PON-1 is located on a subfraction of HDL that contain APO A1 and 
Clusterin (APO-J).
71
 
 In addition to HDL, PON-1 is associated with Tgl rich lipoproteins 
like postprandial VLDL and chylomicrons  but not with LDL.
72
 
STRUCTURE:  
 PON-1 contains six bladed beta propeller and each blade has 4 
strands. In the central tunnel of PON propeller there are two calcium ions 
which are 7.4A˚apart.The calcium ion in the central section is stabilizing 
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this structure, because its dissociation leads to irreversible denaturation of 
protein. The calcium ion in the upper section is catalytic and its removal 
results in inactivation of PON towards paraoxon and phenyl acetate.  The 
unique active site lid is also involved in HDL binding.
69, 74, 75
 Mature 
protein of PON-1 retains its hydrophobic signal sequence on the N-
terminal region from which, methionine residue is removed. The retained 
N terminal signal peptide is essential for the association of PON-1 with 
HDL. 
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FUNCTIONS OF PON-1 
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FUNCTIONS OF PON-1: 
 PON-1 possess lactonase, arylesterase and organophosphatase 
activities.
76
 
 PON-1 hydrolyzes oxons of insecticides like chlorpyrifos, diazinon 
and parathion. 
 PON-1 also hydrolyzes nerve agents like Soman and Sarin.77 
 PON-1 hydrolyzes esters like phenyl acetate, thiophenylacetate  and 
2-naphthyl acetate 
 PON-1 also hydrolyzes aromatic and aliphatic lactones as well as 
cyclic carbonates like dihydrocoumarin, homogentisic acid 
lactone,butyrolactone.
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 It also catalyzes the reverse reaction, lactonisation of  and  
hydroxy carboxylic acids.
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 PON-1 metabolises lactone and cyclic carbonate containing drugs  
like Prolifloxacin, Spironolactone, Lovastatin, Simvastatin and 
Mevastatin. It is also responsible for Pilocarpine hydrolysis.
78,79
 
 It also has low levels phospholipase-A2  and  peroxidase activity.
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 PON-1 possesses antiatherogenic activity. It protects both HDL and 
LDL from oxidation by its ability to hydrolyze specific oxidised 
phospholipids and cholesteryl linoleate hydroperoxides in oxidised 
LDL, and also decreases the macrophage uptake of OX- LDL.
81
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 PON-1 reduces the OX-LDL induced MCP-1 production by 
endothelial cells.
77
 
 It also protects proteins against N-homocysteinylation by 
hydrolyzing homocysteine  thiolactone.
82,83
 
 It degrades bioactive phospholipids such as platelet activating factor 
thereby prevents intravascular coagulation.
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 PON metabolizes 5-OH eicosatetraenoic acid and 1,5 lactone and 4-
OH docosahexaenoic acid which are the products of both enzymatic 
and non-enzymatic oxidation of arachidonic acid and 
docosahexaenoic acid respectively and may represent PON’s 
endogenous substrates.
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PARAOXONASE-2: 
           PON-2 is expressed in many tissues like liver, lungs, testis, placenta, 
heart and arterial wall cells.
84 
 It is an intracellular protein found in endoplasmic reticulum and 
nuclear membrane.
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 The molecular mass is approximately 44kDa.84 
 It is secreted from the cell only in small amounts and the enzyme 
may be rapidly degraded following secretion.
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  It is not associated with lipoproteins. 
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 It has got antioxidant properties and it decreases the oxidation of 
LDL.It also able to reverse the oxidation of minimally modified 
LDL (mm LDL). 
 It lacks paraoxon and phenyl acetate hydrolyzing activity.65 
PARAOXONASE-3: 
 PON-3 is discovered at the last. It is synthesised in the liver and is 
present along with HDL in serum, but in much minute levels than 
PON-1. 
 it is also expressed in kidneys.84 
 The molecular mass is 40 kDa.  
 It has got antioxidant properties and it prevents formation of 
minimally modified LDL and inhibits minimally modified LDL 
induced monocyte chemotactic activity. 
 PON-3 is similar to PON-1 but differs from its substrate specificity. 
PON-3 lacks paraoxon and phenyl acetate hydrolysing activity and 
is not regulated by Oxidised lipids and by inflammatory changes.
65
 
 Of the three, PON-1 is the most investigated and best understood 
member of PON family. 
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PON AND HDL: 
 PON-1 is an important component of HDL responsible for the ability 
of HDL to prevent LDL peroxidation.
85
 
 PON-1 is located on a subfraction of HDL that contains APO A1  and 
clusterin (APO-J).
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 PON-1 activity is highest in HDL-3 and APO-J containing HDL87. 
 Association of PON-1 with HDL is necessary for maintaining the 
normal serum activity. 
 PON-1 is anchored to the HDL lipids by its hydrophobic N-terminal 
end, and also to be bound to APO-A1. 
 The N- terminal  hydrophobic signal peptide is the structural 
requirement for binding of PON-1 to HDL and HDL provides the 
optimal physiological acceptor complex which stimulates secretion 
and stabilizes the secreted enzyme.
73
 
 The conformation of enzyme within the hydrophobic environment of 
HDL is crucial for its activity.
88
 
 HDL is bound on the cell membrane via scavenger receptor B1 
(SRB1). PON-1 which was inserted in to the external surface of the 
cell membrane is then transferred on HDL during transient 
association of the lipoprotein with the cell.
89
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 Serum PON-1 activity and concentration are correlated with HDL-
cholesterol and APO A1 concentration in most healthy population 
but the relationship is not a strong one, as the PON-1 containing 
HDL being a subspecies, the concentration of which can vary 
considerably, independently of the major part of HDL.
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 Changes in ratio of HDL subfraction may alter the stability and 
antioxidant capacity of PON-1.
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ANTI ATHEROGENIC ROLE OF HDL:  
Traditionally, the role of HDL in reverse cholesterol transport has 
been involved to explain its anti atherosclerotic action. Small HDL 
precursors known as pre β HDL, in the tissue fluid take free cholesterol 
from the cell membranes. Once on the pre β particle, the free cholesterol is 
esterified by the action of LCAT (Lecithin cholesterol acyl transferase) 
which renders it more hydrophobic. The cholesterol ester moves to the 
centre of the particle and gradient for the movement of free cholesterol 
from the cell membrane to the pre β HDL is established. Continued uptake 
of cholesterol results in formation of larger α migrating HDL3, which 
diffuse from the tissue fluid in to the plasma. Once in the circulation, HDL 
remodelling occurs through the action of CETP (cholesterol ester transfer 
protein), PLTP (phospholipid transfer protein), hepatic and lipoprotein 
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lipase and the transfer of apolipoproteins from other lipoproteins, resulting 
in mixture of HDL2, and HDL3, which fall into two main categories. 
  1) Those containing apoA1 but no apoA2  
 2) Those containing both.  
The fate of cholesterol within the HDL pool, can be taken up by the liver 
for reuse or it can be transferred back to VLDL or LDL by CETP.
90
         
TWO THEORIES OF ANTI OXIDATIVE ACTION OF HDL 
                    Two overlapping theories are 1) Direct Metabolism and 2) 
Transfer theories. 
                   In Direct Metabolism theory, HDL comes in contact with LDL 
in the sub intimal space and acts to prevent LDL oxidation, by hydrolyzing 
lipid hydroperoxides, with the help of   PON-1.It is shown that in the 
absence of PON- 1, HDL is unable to destroy the biologically active lipids 
in oxidized LDL. 
                   In Transfer theory, HDL acted to protect LDL against lipid 
peroxidation, by acting as a reservoir for lipid peroxides generated on LDL 
and therefore breaking the chain of lipid peroxide propagation. Once 
attached to HDL, phospholipid hydroperoxides (PLHP)  could be 
hydrolysed by HDL associated PON-1, Platelet activating factor acetyl 
hydrolase(PAF-AH),and LCAT either singly, or in combination to give 
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non –atherogenic products, or could be transferred to cholesterol by LCAT 
to form oxidized cholesteryl esters in HDL.HDL then transfers the 
oxidized cholesteryl esters to the liver for disposal.
63,64,65 
Thus the 
protective effect of HDL may not be dependant on the absolute levels of 
HDL cholesterol in the blood, but rather the abundance of HDL particles 
which contains the protective enzymes PON-1and PAF-AH.
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REGULATION OF PON ACTIVITY: 
GENETIC FACTORS: 
  The serum level of PON 1 in an individual is relatively stable over 
time; where as the enzymatic activity of PON 1 varies among individuals 
by 10- 40 folds. The inter individual variability is due to amino acid 
polymorphism.
93 
PON 1 has 2 amino acid polymorphism, one at position-
55(methionine/ leucine) PON-1 L55M, other at position 192(arginine / 
glutamine) PON-1 Q192R. Paraoxon hydrolytic activity is greatest with 
PON-1-192RR and PON-55 LL individuals, and least with PON- 1 192 
QQ and PON 1 55MM.  Heterozygotes have intermediate levels of activity. 
On the other hand, the capacity of PON alloenzymes to protect LDL from 
oxidation is the complete reversal of paraoxon hydrolytic activity. The 
PON1 55MM / PON1 192 QQ is associated with greatest protective 
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capacity. These alloenzymes are also most active in hydrolyzing diazoxon 
and nerve gases Sarin and Soman.
72,94 
All alloenzymes have similar hydrolytic activity on phenylacetate, 
2naphthylacetate, chlorpyrifos oxon etc. Glu 192 Arg polymorphism 
results in decrease in serum PON activity possibly caused by decreased 
affinity of the Arg 192 polymorphism to the HDL which leads to decreased 
protein stability and activity.
72,94
 
NON-GENETIC FACTORS: 
DIET:   
 Diet rich in trans-unsaturated fat markedly decreases PON1 
activity.
65,69,73
    
 Consumption of degraded cooking oil lowers PON1 activity
95 
 Alcohol and vitamin C and E elevate its activity.
69,96 
 Oleic acid from olive oil increases PON-1’s activity. 
 Nutritional antioxidants such as carotenoids (lycopene and beta 
carotene) and  polyphenols (pomegranate, red wine,tea, soy, 
liqourice root& grapes) increases PON-1 activity.
65,69,73 
ENVIRONMENTAL FACTORS: 
 Oxidative stress leads to enzyme inactivation.
97 
 Smoking decreases  PON1 activity.
97
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 Exposure to chemicals like organophosphorus causes long term 
decrease in PON1 activity.
69,73 
 Statins and fibrates  increases  PON1 activity by upregulating the 
gene  expression.
98,99 
 Decrease in serum PON1 activity may occur as a part of 
inflammatory response by cytokines.
100 
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AIMS AND OBJECTIVES 
AIM: 
To estimate the levels of serum Paraoxonase-1 in patients with 
metabolic syndrome and to compare the levels with healthy controls. 
OBJECTIVES: 
              1) To estimate the relationship of serum paraoxonase-1activity 
with the components of fasting glucose levels, lipid profile, blood pressure 
and waist circumference. 
             2) To correlate serum Paraoxonase level with the malondialdehyde 
levels. 
             3) To evaluate the association of Paraoxonase -1 activity & 
malondialdehyde levels with components of metabolic syndrome. 
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MATERIALS AND METHODS 
The study was conducted, at Thanjavur Medical College, Thanjavur, 
after getting approval from the ethical committee of Thanjavur medical 
college, Thanjavur. 
Hundred subjects were chosen for the study. Both males and females 
in the age group of 21-60 years were included and informed consent were 
obtained from all of them. The study population includes 2 groups: 
Control group consists of 50 healthy individuals and Study group 
consists of 50 patients with metabolic syndrome.  
INCLUSION CRITERIA:- 
Patients with components of metabolic syndrome were included in 
the study 
EXCLUSION CRITERIA:- 
 Acute and chronic infections 
 Chronic inflammatory disorders 
 Thyroid disorders 
  Smoking 
  Chronic Alcoholism 
 Liver diseases 
 Renal failure 
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SAMPLE COLLECTION:- 
Under aseptic precautions, fasting venous blood sample of 6ml was 
collected from each subject .The vacutainers containing the blood samples 
were kept at room temperature for 30 min and were centrifuged at 2000 
rpm for 15 minutes for clear separation of serum .The following 
parameters were estimated, immediately after the serum was separated. 
1) Paraoxonase activity 
2) Glucose  
5) Total cholesterol  
6) HDL cholesterol 
7) Triacyl glycerol 
8) Malondialdehyde 
LDL and VLDL cholesterol levels were calculated from the 
estimated parameters. 
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Materials used for study: 
1. Proforma – to   record   the   anthropometric   measurements   of    the   
subjects  and    the clinical   findings.  
2. Portable weighing  machine – to  record   the  body   weight   in   
kilograms. 
3. Non elastic   inch tape - to measure   Waist   circumference   in 
centimeters. 
4. Standardized    mercury   sphygmomanometer – to   record   the    Blood 
Pressure. 
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ESTIMATION OF SERUM PON-1 ACTIVITY: 
PON-1 activity was estimated using the paraoxon (O,O diethyl-O-4 
nitro phenyl phosphate) as the substrate for hydrolysis. The chemicals used 
were of analytical reagent grade from Sigma chemicals. 
PRINCIPLE: 
Serum Paraoxonase1 hydrolyses paraoxon in the presence of 
calcium, at pH 8.0 at 25
˚
 C and releases Para nitro phenol (P-NP).The 
liberated P-NP is measured, and the activity of PON can be calculated 
using the molar absorption of  P-NP in a kinetic assay.The absorbance was 
measured at 405nm.One unit (1U)of PON activity is defined as 1micromol 
of para nitro phenol formed per minute per litre at 25˚c and the activity was 
expressed as U/L of serum. 
Paraoxon+H2O                  Di ethyl phosphate +P-nitro phenol 
REAGENTS:- 
 The assay mixture consists of 2.2mM paraoxone substrate in 0.1M 
Tris Hcl buffer, PH 8.0 containing 2Mm CaCl2. 
 
 
 
   Paraoxonase 
68 
 
REAGENT PREPARATION:- 
BUFFER:-    
 0.1M TRIS: 12.114gm of Tris is dissolved in 1000 ml of 
distilled water. 
 0.1M Hcl:  1ml of 10 molar solution of Hcl in 99ml of 
distilled water. 
 2mM CaCl2: 294.04mg of Calcium chloride is dissolved along 
with Tris. 
      To prepare this buffer, 90ml of Tris solution is taken and 0.1M Hcl is 
added till Ph 8.0 is obtained. The buffer solution is refrigerated. 
SUBSTRATE PREPARATION:-   
      2mM paraoxon is needed. To achieve this 3µl of the paraoxon is added 
to 6.355ml of the buffer. This is freshly prepared. 
MOLAR ABSORPTIVITY OF PARA NITRO PHENOL:- 
      The micro molar absorptivity of P-nitro phenol is measured as follows 
 Molecular weight of P-NP=139.11 g /mol 
 1 micromole=139.1µgm/L 
      The amount is weighed and dissolved in the buffer and the absorption 
is read at 405nm in the semi auto analyser. 
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      As per Beer’s law: A=  b c       
A=Absorption, = Absorptivity, b = path length, c = concentration of the 
substance. 
 = A/ bc, where b=1cm,c=1 µmol. 
Micro molar absorptivity=0.034/ 1x1           
       Delta absorbance / min x Total volume x1000 
Enzyme activity U/L = ------------------------------------------------------------ 
                                   
 
 Factor can be calculated by the formula 
 
                                             Total volume x1000    
 F =               ------------------------------------------------------------------    
                      Sample volume x micro molar absorptivity x path length  
                    
     =  550x1000/ 50x0.034 x1 
         Factor =374 
        Thus enzyme activity U/L=Δ Absorbance x374 
 
 
 
 
   Sample volume x micromolar absorptivity x path length 
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ASSAY PARAMETERS:-   
 MODE :- Kinetic mode  
 WAVELENGTH:- 405nm 
 SAMPLE VOLUME:- 50µl 
 REAGENT VOLUME:-500µl 
 LAG TIME:-60 sec 
 KINETIC INTERVAL:-180sec 
 NUMBER OF READINGS:- 3 
 FACTOR:-374 
 REACTION TEMPERATURE:-25˚C           
 REACTION DIRECTION:-Increasing    
 UNITS:-  U/ L 
ASSAY PROCEDURE:-  
500µl of the reagent and 50µl of the sample were taken, mixed well 
and read at 405nm using the semi auto analyzer. 
NORMAL RANGE: 90-200 U/L INTERFERENCES: Haemolysed 
serum 
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ESTIMATION OF TOTAL CHOLESTEROL 
METHOD: Cholesterol oxidase-Peroxidase Enzymatic, endpoint 
method. 
PRINCIPLE:  
The free cholesterol, liberated from the cholesterol esters by 
cholesterol esterase, is oxidised by cholesterol oxidase to cholestenone 
with the simultaneous production of hydrogen peroxide. The hydrogen 
peroxide reacts with 4 amino antipyrine and a phenolic compound in the 
presence of peroxidase to yield a red coloured complex.  
1. Cholesterol ester +water            CHE      cholesterol + fatty acid 
2. Cholesterol + oxygen                CHO            cholest-4-en-3one +H 2O2    
3. 2 H2O2 + 4AAP+ phenol           POD            quinoneimine dye + 4H2O 
•CHE- Cholesterol esterase                    • CHO- Cholesterol oxidase 
•4AAP- 4 amino antipyrine                    • POD- Peroxidase 
Absorbance of quinoneimine formed is directly proportional to the 
concentration of cholesterol. 
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Reconstituted reagent: 
Dissolve the contents of one bottle of the reagent-1(Chromogen/Enzyme) 
with one bottle of reagent-1A (BUFFER) 
ASSAY PROCEDURE: Taken three test tubes and marked as Blank, 
Standard,Test.Taken working Reagent of about 1000 µl into each test 
tubes. Then 10 µl of Distilled water was added in  the blank,10 µl of std 
(200mg/dl ) was added in the test tube marked as standard and in the tube 
marked as test - 10 µl of patient sample was added. 
                 Mixed well and incubated for 10 min at room temperature. The 
absorbance of the test and standard were read against reagent blank at 
wavelength of 505 nm. 
CALCULATION: 
                                Absorbance of test       
Cholesterol     =    ------------------------ ×concentration of standard(mg/dl)                                
                              Absorbance of standard   
                                                                                          
REFERENCE RANGE: 150-200 mg/dl          
 Linearity –up to 750 mg/dl,Sensitivity-1mg/dl 
INTERFERENCE:  Hb upto 200mg/dl, Ascorbate upto 12mg/dl, 
Bilirubin upto 10mg/dl and Triglycerides upto700 mg/dl do not interfere 
with the test 
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ESTIMATION OF TRIGLYCERIDES 
METHOD: GPO-PAP method, endpoint 
METHODOLOGY: 
Colorimetric, enzymatic method with glycerol phosphate oxidase. 
PRINCIPLE: 
TGL reacts with water in presence of Lipoprotein lipase it forms 
Glycerol and free fatty acids. Glycerol reacts with ATP in the presence of 
Glycerol Kinase it forms Glycerol 3 phosphate and ADP. Glycerol 3 
phosphate reacts with oxygen in presence of Glycerol 3 phosphate oxidase 
it forms Dihydroxy Acetone Phosphate and Hydrogen Peroxide. Hydrogen 
Peroxide reacts with 4Amino Anti Pyrine and 3,5Dichloro-2Hydroxy 
Benzene Sulfonate in presence of peroxidase Quinoneimine dye and two 
water molecules are formed. 
 The intensity of Quinoneimine dye formed is proportional to the   
concentration of Triglycerides present in the sample, when measured at 
505 nm (500-540nm). 
 
 
 
  
74 
 
REAGENT PREPARATION: 
      The working reagent was prepared by mixing 4 parts of 
R1(Enzymes/chromogen) with 1 part of R2(Buffer).Stable for 90 days at 2-
8 
◦
C.  
Sample:  Unhemolysed serum collected after 12 hrs of fasting. 
ASSAY PROCEDURE: 
           Taken three test tubes and marked as Blank, Standard,Test.Taken 
working Reagent of about 1000 µl into each test tubes. Then 10 µl of 
Distilled water was added in  the blank,10 µl of std (200mg/dl ) was added 
in the test tube marked as standard and in the tube marked as test - 10 µl of 
patient sample was added. 
            Mixed and incubated for 10min,at room temperature . Absorbance  
were read at 505nm for standard and sample against reagent blank. 
CALCULATION: 
   Triglycerides (mg/dl)      =   Absorbance of test    x Concentration of standard  
                                               Absorbance of standard      
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REFERENCE VALUES: 
Serum/plasma 37
◦
C 
Normal fasting level 25-160mg/dl 
 
Linearity – upto 1000mg/dl,Sensitivity- 2mg/dl 
INTERFERENCE:- 
Hb upto300mg/dl, 
Ascorbate upto 3mg/dl, 
Bilirubin upto 20mg/dl do not interfere with the test. 
ESTIMATION OF HDL CHOLESTEROL: 
 METHOD: Phosphotungstic acid method,endpoint 
PRINCIPLE: 
  Chylomicrons (CM), LDL and VLDL are precipitated from serum or 
plasma with phospho tungstate in the presence of divalent cations such as 
Magnesium.The HDL cholesterol remains unaffected in the supernatant 
and is estimated using cholesterol reagent.                   
      
Serum/plasma                                             HDL      +     (LDL+VLDL+CM) 
               (Supernatant)       (Precipitate) 
 
   Phosphotungstic acid, Mg2+ 
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REAGENT COMPOSITION: 
Reagent1: precipitating reagent 
Phosphotungstic acid 2.4mmol/l 
Magnesium chloride 40mmol/l 
 
HDL cholesterol standard – 25mg/dl 
SAMPLE: Unhemolysed serum used 
PRECIPITATION: 
Precipitation of LDL, VLDL and Chylomicrons done as follows: 
 
 
 
Mixed well and the reaction mixture was allowed to stand for 10 min 
at room temperature, centrifuged at 4000 rpm for 10min and obtain a clear 
supernatant. The supernatant was used to determine the concentration of 
HDL cholesterol in the sample. 
 
 
Pipette Volume 
Sample 250µl 
Precipitating reagent 500µl 
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ASSAY PROCEDURE: 
Mixed well and incubated for 10 min at room temperature. The absorbance 
of the standard and the test samples were read at 505 nm against reagent 
blank. 
CALCULATION 
HDL cholesterol (mg/dl)=  Absorbance of test      x conc.of standard x dilution factor                                                        
                                          Absorbance of standard                                           
      =    Absorbance of the test    x 25x3 
                                         Absorbance of the standard  
      =    Absorbance of the test      x 75 
                                     Absorbance of the standard 
Linearity-upto 125mg/dl 
NORMAL VALUES : 
Males- 40to 65mg/dl 
Females-45to80mg/dl 
Pipette into tubes marked Blank Standard Test 
Cholesterol working reagent 1000µl 1000µl 1000µl 
Distilled water 50µl - - 
HDL standard - 50µl - 
Supernatant - - 50µl 
78 
 
INTERFERENCE: 
High triglyceride concentration above 300 mg/dl cause interference 
with the assay. 
Bilirubin and ascorbate at high concentrations interfere with 
precipitation. 
Friedewald’s formula for calculation of LDL 
VLDL=TGL/5,if TGL is less than 400mg/dl 
LDL = Total cholesterol – (HDL + VLDL) 
Estimation of Urea by Di acetyl Monoxime method   
Estimation of creatinine by Jaffe’s method. 
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ESTIMATION OF GLUCOSE 
METHOD: Glucose oxidase- peroxidase method, end point/fixed time 
PRINCIPLE: Glucose in the sample is oxidized to yield gluconic acid and 
hydrogen peroxide in the presence of glucose oxidase. The enzyme 
peroxidase catalyses oxidative coupling of  4 –amino antipyrine  with 
phenol to yield a coloured complex of quinoneimine , with absorbance is 
proportional to the concentration of glucose in the sample. 
Glucose standard : 100mg/dl 
Specimen: Fresh unhemolysed serum used 
ASSAY PROCEDURE: 
           Taken three test tubes and marked as Blank, Standard,Test.Taken 
working Reagent of about 1000 µl into each test tubes. Then 10 µl of 
Distilled water was added in  the blank,10 µl of std (100mg/dl ) was added 
in the test tube marked as standard and in the tube marked as test - 10 µl of 
patient sample was added. 
        Mixed well and incubated at 37
◦
C for 5 min. The absorbance of the 
standard and the test were read against reagent blank at 505nm. 
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CALCULATION: 
Glucose (mg/dl) =     Absorbance of test           x concentration of standard(100mg/dl) 
                                   Absorbance of standard  
Linearity upto 500mg/dl by endpoint method. 
NORMAL VALUES:     
- Glucose fasting= 70-110 mg/dl 
- Glucose postprandial= 90-140 mg/dl. 
Estimation of Malondialdehyde (MDA)  by Thio Barbituric Acid 
reactivity assay method: 
 Serum MDA was measured by thiobarbituric acid reactivity assay 
method of Satoh. Serum MDA can be measured by various methods 
including its reactivity with thiobarbituric acid. In spite of many cross-
reacting substances are found to increase the color when MDA is measured 
by this method, thiobarbituric acid reacting substances (TBARS) is the 
most widely used method for the estimation of MDA because it is 
relatively inexpensive and very easy to perform. 
 
 
81 
 
Principle: 
The proteins are precipitated by trichloroacetic acid. Sulphuric acid 
hydrolyses the lipid peroxides from the protein to yield a malondialdehyde 
(MDA). This MDA reacts with thiobarbituric acid (TBA) to produce 
MDA-TBA adduct. On boiling in water bath, this gives a pink color, which 
is measured at absorbance of 535 nm using n-butanol as blank. 
Reagents: 
 Trichloroacetic acid (TCA): 20% solution 
 Thiobarbituric acid (TBA): 0.22% solution in 2M sodium sulphate 
 Sulphuric acid (0.05 M) 
Procedure: 
1. In a centrifuge tube, 250μL serum diluted with 250μL distilled water 
was taken and mixed with 2.5ml 20% TCA and kept for 10 min for 
precipitation of proteins 
2. Precipitated proteins were separated by centrifuge at 3500 rpm for 
10 min. 
3. The supernatant was discarded and the protein pellet was washed 
with 2ml of 0.05M sulphuricacid. 
4. Precipitate was then incubated with 2ml of 0.05M sulphuricacid and 
3ml of TBA reagent in a boiling water bath for 30 min. 
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5. After 30 min, the centrifuge tubes were cooled immediately under 
tap water to arrest the reaction. 
6. Once the tubes were cooled, 4ml of butanol was added and mixed 
vigorously using a vortex machine. 
7. Further the tubes were centrifuged at 3500 rpm for 10 min to obtain 
a clear supernatant. 
8. Absorbance of supernatant was measured at 530nm using 
photoelectric calorimeter.  
Calculation: 
Concentration of MDA in serum = 102.56 × A μmol/L, where A is 
absorbance value. 
Molar extinction coefficient of MDA = 1.56 ×10
5
M/L/cm 
Values were expressed inμmoles/L. 
Reference range: 
Serum MDA: 2-5 μmoles/
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MASTER CHART –I   CONTROL GROUP 
S.NO AGE 
yrs 
SEX SBP DBP W C 
cm 
WEIGHT 
Kg 
HEIGHT 
mts 
BMI 
Kg/m
2
 
 
MDA 
µmol/L 
 
PON 
ACT 
U/L 
FBS 
mg/dl 
PPBS 
mg/dl 
                  LIPID   PROFILE (mg/dl) 
  
  
  
  
UREA 
mg/dl 
CREA 
mg/dl 
1 39 F 128 78 84 51 1.58 20.42942 1.025 165 84 120 144 110 45 77 22 26 0.8 
2 25 F 120 80 81 48 1.58 19.22769 1.025 211 98 130 131 102 51 59.6 20.4 28 0.9 
3 28 F 110 80 81 48 1.55 19.97919 1.025 179 84 124 140 106 51 67.8 21.2 32 1 
4 37 F 120 78 80 56 1.54 23.61275 2.05 162 87 128 120 90 52 50 18 28 0.9 
5 34 F 124 82 78 67 1.58 26.83865 3.076 143 84 116 165 123 51 89.4 24.6 36 1.2 
6 45 F 128 84 83 49 1.59 19.38214 2.05 168 96 130 134 102 48 65.6 20.4 38 1.2 
7 35 F 124 82 78 69 1.54 29.09428 6.153 105 85 126 182 139 54 100.2 27.8 28 1 
8 58 F 130 78 84 51 1.62 19.43301 2.05 173 99 130 138 101 51 66.8 20.2 28 0.9 
9 44 F 118 84 83 69 1.52 29.86496 4.102 118 95 132 162 132 42 93.6 26.4 22 0.6 
10 21 F 120 80 80 44 1.59 17.40437 2.05 184 96 136 131 100 50 61 20 28 0.8 
11 60 F 128 84 86 62 1.61 23.91883 3.076 149 88 132 174 99 42 112.2 19.8 28 0.7 
12 50 F 120 82 84 56 1.54 23.61275 3.076 130 98 138 151 119 45 82.2 23.8 28 0.9 
13 52 F 126 84 85 62 1.54 26.14269 4.102 115 99 139 181 131 43 111.8 26.2 34 1 
14 44 F 128 80 99 78 1.66 28.306 5.128 119 94 136 184 142 40 115.6 28.4 30 1 
15 41 F 126 78 80 46 1.58 18.42653 2.05 174 88 126 135 89 53 64.2 17.8 32 0.8 
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16 30 F 120 76 78 48 1.62 18.28989 1.025 197 99 135 132 101 45 66.8 20.2 30 0.8 
17 46 F 130 84 83 49 1.55 20.39542 1.025 200 97 137 125 102 50 54.6 20.4 28 1 
18 54 F 128 80 96 52 1.48 23.73996 3.076 145 98 134 164 133 41 96.4 26.6 34 0.9 
19 51 F 128 82 85 52 1.65 19.10009 3.076 128 99 137 141 105 45 75 21 34 0.8 
20 53 F 124 80 88 53 1.52 22.93975 4.102 162 98 139 163 121 43 95.8 24.2 32 1 
21 42 F 128 80 99 69 1.59 27.29322 5.128 117 92 126 172 142 41 102.6 28.4 28 0.8 
22 38 F 126 78 80 46 1.59 18.19548 2.05 171 90 138 152 117 49 79.6 23.4 34 0.8 
23 32 F 124 76 78 47 1.61 18.13202 2.05 185 84 112 141 112 51 67.6 22.4 22 0.9 
24 43 F 128 80 82 69 1.55 28.72008 5.128 108 98 139 162 130 45 91 26 38 1.2 
25 30 F 120 76 78 57 1.56 23.42209 3.076 152 96 138 139 115 50 66 23 30 0.9 
26 45 M 126 78 88 65 1.68 23.03005 2.05 155 87 110 131 102 42 68.6 20.4 28 0.8 
27 57 M 128 80 99 84 1.74 27.74475 5.128 101 98 126 181 135 41 113 27 30 0.9 
28 52 M 136 80 96 69 1.58 27.6398 4.102 112 88 108 178 142 41 108.6 28.4 26 0.9 
29 50 M 128 80 95 73 1.68 25.86451 4.102 130 99 132 183 148 45 108.4 29.6 34 1.1 
30 35 M 124 82 88 73 1.62 27.81588 4.102 119 84 124 178 148 52 96.4 29.6 30 0.9 
31 46 M 130 78 101 63 1.65 23.1405 1.025 195 88 110 134 94 50 65.2 18.8 28 0.9 
32 43 M 128 84 89 80 1.78 25.24934 3.076 138 95 130 145 105 43 81 21 30 0.9 
33 52 M 130 82 93 74 1.74 24.4418 1.025 193 90 129 138 102 44 73.6 20.4 34 0.8 
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34 48 M 116 80 99 66 1.73 22.05219 4.102 131 93 131 164 133 46 91.4 26.6 26 0.7 
35 25 M 120 80 98 52 1.67 18.64534 1.025 199 84 125 128 99 48 60.2 19.8 22 0.6 
36 35 M 124 82 98 63 1.7 21.79931 2.05 163 84 129 127 102 52 54.6 20.4 28 0.8 
37 45 M 118 84 92 70 1.69 24.50895 3.076 143 96 138 156 126 44 86.8 25.2 24 0.9 
38 38 M 120 78 88 65 1.73 21.71807 2.05 194 86 129 128 96 56 52.8 19.2 26 0.8 
39 28 M 110 76 98 62 1.59 24.52435 2.05 160 89 123 131 100 54 57 20 30 1 
40 55 M 130 78 101 83 1.72 28.05571 4.102 108 84 121 190 146 40 120.8 29.2 28 0.9 
41 42 M 130 84 89 66 1.72 22.30936 2.05 173 94 131 130 94 50 61.2 18.8 34 0.9 
42 21 M 120 80 88 62 1.68 21.96712 2.05 175 86 119 142 112 51 68.6 22.4 24 0.6 
43 55 M 130 78 92 73 1.62 27.81588 3.076 159 97 138 149 129 46 77.2 25.8 28 0.9 
44 23 M 120 80 99 62 1.62 23.62445 2.05 192 78 119 153 113 52 78.4 22.6 24 0.6 
45 38 M 126 82 100 72 1.61 27.77671 2.05 163 85 122 156 127 50 80.6 25.4 36 0.8 
46 47 M 130 80 89 66 1.74 21.79945 1.025 195 92 132 131 90 54 59 18 38 1 
47 34 M 120 76 98 63 1.69 22.05805 2.05 169 86 117 142 113 52 67.4 22.6 36 1.2 
48 56 M 130 78 92 74 1.64 27.51338 3.076 150 99 136 152 92 50 83.6 18.4 26 0.6 
49 60 M 136 80 98 79 1.63 29.7339 6.153 100 99 135 184 146 42 112.8 29.2 28 1 
50 51 M 130 82 94 75 1.7 25.95156 2.05 165 97 133 133 99 48 65.2 19.8 30 0.8 
86 
 
 
MASTER CHART – II STUDY GROUP 
 
S.NO 
 
AGE 
 
SEX 
 
SBP 
 
DBP 
 
W C 
 
Wt 
 
Ht 
 
BMI 
 
MDA 
 
PON                     
ACT 
 
FBS
 
PPBS 
                
LIPID   PROFILE(mg/dl) 
 
 
UREA 
 
CREAT 
          mm Hg cms    Kg  mts   μmoles/L    
U/L 
mg/dl mg/dl T.CHO TGL HDL LDL VLDL mg/dl mg/dl 
1 36 F 128 82 106 95 1.72 32.11 7.179 67.3 108 129 195 156 36 127.8 31.2 20 0.6 
2 49 F 138 86 119 80 1.54 33.73 9.23 45.6 110 143 211 180 41 134 36 28 0.9 
3 33 F 128 80 108 81 1.58 32.45 7.179 66.7 92 104 192 152 40 121.6 30.4 30 1 
4 48 F 140 90 117 85 1.65 31.22 8.204 52.6 111 151 207 166 36 137.8 33.2 26 1 
5 23 F 130 82 112 82 1.58 32.85 7.179 62.9 92 110 195 154 39 125.2 30.8 26 0.8 
6 28 F 120 80 103 79 1.59 31.25 6.156 76.9 100 163 185 144 38 118.2 28.8 28 0.9 
7 38 F 136 86 114 86 1.6 33.59 8.204 56.4 105 145 209 168 35 140.4 33.6 32 0.8 
8 48 F 138 88 117 82 1.56 33.69 9.23 41.2 102 147 202 184 32 133.2 36.8 34 1 
9 54 F 138 88 115 96 1.69 33.61 8.204 51.4 109 157 207 162 40 134.6 32.4 32 0.8 
10 41 F 130 86 103 79 1.59 31.25 6.156 77.5 104 146 182 142 45 108.6 28.4 28 0.9 
11 60 F 140 90 132 102 1.65 37.47 12.256 19.2 125 193 256 205 28 187 41 32 0.8 
12 21 F 120 80 97 79 1.59 31.25 5.128 75.4 100 131 175 132 44 104.6 26.4 24 0.6 
13 49 F 138 86 119 89 1.64 33.09 8.204 55.7 120 163 208 168 39 135.4 33.6 22 0.8 
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14 25 F 128 80 96 80 1.62 30.48 5.128 85.7 100 136 172 132 45 100.6 26.4 36 1.1 
15 42 F 130 86 102 78 1.55 32.47 6.156 78.4 103 135 184 140 41 115 28 30 0.9 
16 57 F 138 88 124 96 1.68 34.01 11.281 30.4 114 168 224 198 28 156.4 39.6 34 1 
17 56 F 138 86 122 88 1.59 34.81 10.256 34.6 113 162 216 192 30 147.6 38.4 24 0.7 
18 45 F 140 88 118 86 1.6 33.59 9.23 49.4 110 157 213 185 38 138 37 28 1 
19 50 F 140 90 128 92 1.58 36.85 11.281 29.4 124 187 236 200 30 166 40 34 1 
20 31 F 120 80 85 83 1.68 29.41 4.104 80.2 100 140 155 126 44 85.8 25.2 34 1 
21 45 F 130 86 90 80 1.59 31.64 6.156 76.4 101 142 178 129 37 115.2 25.8 29 0.9 
22 28 F 126 80 109 83 1.6 32.42 7.179 63.2 105 137 192 153 38 123.4 30.6 30 0.8 
23 32 F 120 80 87 70 1.55 29.14 5.128 85.4 85 178 170 151 43 96.8 30.2 26 0.8 
24 53 F 138 88 115 97 1.7 33.56 8.204 53.8 121 186 205 172 40 130.6 34.4 34 0.9 
25 44 F 120 80 93 76 1.55 31.63 6.156 78.7 101 133 179 138 45 106.4 27.6 36 1 
26 46 M 135 80 112 97 1.69 33.96 9.23 48.2 115 150 209 172 33 141.6 34.4 28 0.9 
27 55 M 140 90 110 82 1.58 32.85 8.204 52.7 111 152 203 161 32 138.8 32.2 36 1.2 
28 52 M 140 82 113 85 1.62 32.39 7.179 68.4 120 161 193 156 34 127.8 31.2 32 0.8 
29 38 M 130 84 116 88 1.61 33.95 9.23 47.5 108 142 209 172 32 142.6 34.4 40 1.1 
30 45 M 132 86 100 86 1.68 30.47 5.128 80.3 102 132 172 138 34 110.4 27.6 32 0.9 
31 60 M 140 90 131 98 1.64 36.44 12.256 21.2 124 183 252 201 28 183.8 40.2 36 1.1 
32 28 M 120 80 98 78 1.59 30.85 5.128 86.9 100 122 175 132 37 111.6 26.4 28 0.9 
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33 56 M 144 86 117 92 1.65 33.79 9.23 45.8 108 128 210 175 32 143 35 32 0.9 
34 34 M 130 86 106 89 1.69 31.16 6.156 74.2 107 130 185 146 36 119.8 29.2 32 0.9 
35 42 M 138 88 118 102 1.72 34.48 10.256 33.2 112 172 214 186 30 146.8 37.2 24 0.9 
36 57 M 142 90 108 89 1.65 32.69 7.179 68.9 109 126 196 152 37 128.6 30.4 34 0.9 
37 35 M 130 80 116 90 1.7 31.14 6.156 72.4 106 127 177 138 34 115.4 27.6 28 1 
38 48 M 138 86 105 90 1.73 30.07 6.156 73.9 104 135 186 147 35 121.6 29.4 28 0.9 
39 35 M 130 78 105 84 1.62 32.01 7.179 66.2 102 132 194 153 35 128.4 30.6 34 0.9 
40 52 M 142 88 112 98 1.71 33.51 9.23 48.5 109 142 210 176 34 140.8 35.2 28 1 
41 43 M 144 90 119 105 1.75 34.29 10.256 39.6 120 184 215 190 30 147 38 28 0.8 
42 47 M 136 86 113 98 1.7 33.91 8.204 57.7 102 126 205 164 33 139.2 32.8 32 0.8 
43 51 M 144 92 123 102 1.72 34.48 11.289 32.9 103 131 223 195 29 155 39 28 0.8 
44 21 M 120 80 96 80 1.69 28.01 4.102 94.2 100 132 165 129 43 96.2 25.8 34 1 
45 45 M 138 86 119 96 1.69 33.61 9.23 44.2 116 156 209 178 32 141.4 35.6 28 0.7 
46 25 M 120 78 105 89 1.67 31.91 6.156 77.4 92 102 187 144 36 122.2 28.8 28 0.7 
47 55 M 138 88 120 99 1.7 34.26 10.256 33.2 119 158 219 189 27 154.2 37.8 26 1.1 
48 38 M 128 78 107 95 1.71 32.49 7.179 67.2 108 132 194 155 35 128 31 28 0.9 
49 50 M 140 90 114 95 1.69 33.26 8.204 50.6 113 158 204 166 32 138.8 33.2 24 0.7 
50 23 M 128 80 99 80 1.62 30.48 5.128 86.7 103 139 178 133 38 113.4 26.6 28 1 
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TABLE 1 :Descriptive Statistics of Study and Control Groups  
 
Variables 
 
Control     ( n=50) 
 
Study    ( n=50) 
Min. Max. Mean S.D. Min. Max. Mean S.D. 
AGE 21 60 42.26 10.6939 21.0 60.0 42.340 11.1604 
SBP 110 140 125.84 6.65 120 144 133.18 7.575 
DBP 76 85 80.14 2.408 78 92 84.76 4.118 
WC 78 101 89.1 7.627 85 132 110.26 10.779 
WEIGHT 44 84 62.64 10.883 70 105 88.22 8.237 
HT(mt) 1.48 1.78 1.6258 0.07106 1.54 1.75 1.6418 .05749 
BMI 17.40 29.86 23.65 3.58 28.01 37.47 32.68 1.88 
MDA 1.025 6.153 2.809 1.403 4.102 12.256 7.813 2.097 
PON 100.00 211.00 154.84 30.71 19.20 94.20 59.33 19.07 
FBS 78 99 91.68 6.001 85 125 107.36 8.806 
PPBS 108 139 128.5 8.36 102 193 145.90 21.100 
T.CHO 120 190 150.54 19.775 155 256 198.64 20.632 
TGL 89 148 115.12 18.022 126 205 161.54 22.117 
HDL 40 56 48.36 4.737 28 46 35.38 4.607 
LDL 50 120.8 79.156 
19.5923
9 
91.8 187.0 130.952 20.4404 
VLDL 17.8 29.6 23.024 3.6045 25.2 41.0 32.308 4.4234 
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                                                   TABLE 2 
 
AGE & SEX DISTRIBUTION BETWEEN STUDY & CONTROL 
GROUPS 
 Control (n=50) Study (n=50) Total (n=100) 
Age    
21-40 yrs 20(40%) 19(36%) 39(39%) 
41 to 60 yrs 30(60%) 31(62%) 61(61%) 
 
 
 
 
Sex    
Male (Control) 25 (50%) 0 25 (25%) 
Female (Control) 25 (50%) 0 25 (25%) 
Male (Study) 0 25 (50%) 25 (25%) 
Female (Study) 0 25 (50%) 25 (25%) 
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 TABLE 3 
STATISTICAL ANALYSIS OF S.PARAOXONASE-1 BETWEEN 
STUDY & CONTROL GROUPS 
  
TABLE 4 
STATISTICAL ANALYSIS OF MALONDIALDEHYDE LVELS 
 BETWEEN CONTROL AND STUDY GROUP 
 
T-TEST 
MALONDIALDEHYDE MEAN S.D 
STATISTICAL 
INFERENCE 
Control (n=50) 2.809 1.40  
.000<0.05  Significant Study (n=50) 7.81 2.09 
 
 
T-TEST 
PARAOXONASE-1 MEAN S.D 
STATISTICAL 
INFERENCE 
Control (n=50) 154.84 30.71 
.000<0.05  Significant 
Study (n=50) 59.32 19.0 
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BAR CHART 1  : COMPARISON OF SERUM PARAOXONASE-1 
ACTIVITY BETWEEN CONTROL AND STUDY GROUP 
 
 
 
 
 
BAR CHART 2 : COMPARISON OF MALONDIALDEHYDE 
BETWEEN CONTROL AND STUDY GROUP 
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TABLE 5  
 STATISTICAL ANALYSIS OF BMI BETWEEN CONTROL AND 
STUDY GROUP 
                                                            
 
T-TEST 
BMI MEAN S.D STATISTICAL INFERENCE 
Control (n=50) 
23.653 3.58 
.000<0.05  Significant 
Study (n=50) 
32.68 1.88 
 
TABLE 6  
STATISTICAL ANALYSIS OF WAIST CIRCUMFERANCE 
BETWEEN CONTROL AND STUDY GROUP 
 
 
T-TEST 
WAIST 
CIRCUMFERENCE 
MEAN S.D 
STAISTICAL 
INFERENCE 
Control (n=50) 
89.1 7.62 
.000<0.05 Significant 
Study (n=50) 
110.26 10.77 
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BAR CHART 3  : COMPARISON OF  BMI 
BETWEEN CONTROL AND STUDY GROUP 
 
 
 
BAR CHART 4 : COMPARISON OF WAIST CIRCUMFERANCE 
BETWEEN CONTROL AND STUDY GROUP 
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TABLE 7 
STATISTICAL ANALYSIS OF FBS & PPBS 
BETWEEN CONTROL AND STUDY GROUP 
 
                                                           
           
 
 
 
 
 
T- TEST 
FBS MEAN S.D STATISTICAL INFERENCE 
Control (n=50) 
91.68 6.00 
 
.000<0.05  Significant Study (n=50) 
107.36 8.80 
PPBS    
Control (n=50) 
128.5 8.36 
  
.000<0.05  Significant Study (n=50) 
145.90 21.10 
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BARCHART 5: COMPARISON OF FBS & PPBS 
BETWEEN CONTROL AND STUDY GROUP 
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TABLE 8 
 STATISTICAL ANALYSIS OF SYSTOLIC & DIASTOLIC BP 
BETWEEN CONTROL AND STUDY GROUP 
 
TABLE 9 
 STATISTICAL ANALYSIS OF TGL BETWEEN CONTROL AND  
STUDY GROUP 
 
T – TEST 
TGL MEAN S.D STATISTICAL INFERENCE 
Control (n=50)    115.12 18.02 
.000<0.05  Significant 
Study (n=50) 161.54 22.11 
 
 
T- TEST 
SYSTOLIC BP MEAN S.D STATISTICAL INFERENCE 
Control (n=50)    125.84   6.65 
.000<0.05  Significant 
Study (n=50)     133.18 7.575 
DIASTOLIC BP    
Control (n=50) 80.14 2.408 
 .000<0.05  Significant 
Study (n=50) 84.76 4.118 
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BARCHART 7: COMPARISON OF SBP& DBP(mmHg) 
BETWEEN CONTROL AND STUDY GROUP 
 
 
BAR CHART 8  : COMPARISON OF TGL 
BETWEEN CONTROL AND STUDY GROUP 
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TABLE 10 
 STATISTICAL ANALYSIS OF T.CHOL, HDL, VLDL, LDL 
BETWEEN CONTROL AND STUDY GROUP 
 
T– TEST 
T.CHOL MEAN S.D STATISTICAL INFERENCE 
Control (n=50) 
150.54 19.77 
 
.000<0.05   Significant Study (n=50) 
198.64 20.63 
HDL    
Control (n=50) 
48.36 4.73 
 
.000<0.05   Significant Study (n=50) 
35.38 4.60 
VLDL    
Control (n=50) 
23.024 3.6 
 
.000<0.05   Significant Study (n=50) 
32.30 4.42 
LDL   
 
Control (n=50) 79.156 19.59  
.000<0.05   Significant 
Study (n=50) 
130.95 20.44 
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BAR CHART 9 : COMPARISON OF HDL 
BETWEEN CONTROL AND STUDY GROUP 
 
 
 
BAR   CHART 10 :COMPARISON OF T.CHOL, VLDL, LDL 
BETWEEN CONTROL AND STUDY GROUP 
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TABLE 11 
STATISTICAL ANALYSIS OF PARAOXONASE BETWEEN 3, 4 & 
5 COMPONENTS OF METABOLIC SYNDROME. 
                                                           
PARAOXONASE-I 
ACTIVITY 
Sum of 
Squares 
df 
Mean 
Square 
F Sig. 
Between Groups 11527.77 3 3842.593 28.108 
.000(statistically      
significant) 
 
                                              
 
 
 
 
 
 
 
 
 
102 
 
TABLE 12 
PEARSONS CORRELATION BETWEEN PARAOXONASE AND 
OTHER STUDY PARAMETERS 
 
PON 
CORRELATION 
VALUE 
 
STATISTICAL 
INFERENCE 
AGE -.260
**
 P < 0.01 Significant 
SBP -.650
**
 P <0.01  Significant 
DBP -.663
**
 P < 0.01 Significant 
WC -.907
**
 P < 0.01 Significant 
WEIGHT -.713
**
 P < 0.01 Significant 
BMI -.944
**
 P < 0.01 Significant 
MDA -.955
**
 P < 0.01 Significant 
FBS -.773
**
 P < 0.01 Significant 
PPBS -.575
**
 P < 0.01 Significant 
T.CHOL -.931
**
 P < 0.01 Significant 
TGL -.918
**
 P < 0.01 Significant 
HDL .872
**
 P < 0.01 Significant 
LDL -.937
**
 P < 0.01 Significant 
VLDL -.962
**
 P < 0.01 Significant 
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TABLE 13 
PEARSONS CORRELATION BETWEEN MDA AND OTHER 
STUDY PARAMETERS 
 
MDA CORRELATION VALUE STATISTICAL INFERENCE 
AGE .345
**
 P < 0.01 Significant 
SBP .728
**
 P < 0.01 Significant 
DBP .722
**
 P < 0.01 Significant 
WC .915
**
 P < 0.01 Significant 
WEIGHT .711
**
 P < 0.01 Significant 
HEIGHT .180 P > 0.05 not Significant 
BMI .913
**
 P < 0.01 Significant 
PON -.955
**
 P < 0.01 Significant 
PPBS .562
**
 P < 0.01 Significant 
FBS .816
**
 P < 0.01 Significant 
CHOL .963
**
 P < 0.01 Significant 
TGL .962
**
 P < 0.01 Significant 
HDL -.875
**
 P < 0.01 Significant 
LDL .960
**
 P < 0.01 Significant 
VLDL .962
**
 P < 0.01 Significant 
 
                                         
 
104 
 
TABLE 14 
PEARSONS CORRELATION BETWEEN   BMI   AND OTHER 
STUDY PARAMETERS 
 
 
BMI 
CORRELATION 
VALUE 
STATISTICAL 
INFERENCE 
AGE .255
*
 P < 0.05 Significant 
SBP .638
**
 P < 0.01 Significant 
DBP .635
**
 P < 0.01 Significant 
WC .870
**
 P < 0.01 Significant 
WEIGHT .664
**
 P < 0.01 Significant 
HEIGHT -.064 P > 0.05 not Significant 
MDA .913
**
 P < 0.01 Significant 
PON -.944
**
 P < 0.01 Significant 
FBS .723
**
 P < 0.01 Significant 
PPBS .495
**
 P < 0.01 Significant 
CHOL .905
**
 P < 0.01 Significant 
TGL .881
**
 P < 0.01 Significant 
HDL -.818
**
 P < 0.01 Significant 
LDL .905
**
 P < 0.01 Significant 
VLDL .881
**
 P < 0.01 Significant 
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TABLE 15 
PEARSONS CORRELATION BETWEEN 
TGL  AND OTHER STUDY PARAMETERS 
 
 
TGL 
CORRELATION 
VALUE 
STATISTICAL 
INFERENCE 
AGE .331
**
 P < 0.01 Significant 
SBP .702
**
 P < 0.01 Significant 
DBP .696
**
 P < 0.01 Significant 
WC .901
**
 P < 0.01 Significant 
WEIGHT .680
**
 P < 0.01 Significant 
HEIGHT -.179 P > 0.05 not Significant 
BMI .881
**
 P < 0.01 Significant 
MDA .962
**
 P < 0.01 Significant 
PON -.918
**
 P < 0.01 Significant 
FBS .759
**
 P < 0.01 Significant 
PPBS .613
**
 P < 0.01 Significant 
CHOL .964
**
 P < 0.01 Significant 
HDL -.857
**
 P < 0.01 Significant 
LDL .949
**
 P < 0.01 Significant 
VLDL 1.000
**
 P < 0.01 Significant 
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TABLE 16 
PEARSONS CORRELATION BETWEEN 
HDL  AND OTHER STUDY PARAMETERS 
 
 
HDL CORRELATION VALUE 
STATISTICAL 
INFERENCE 
AGE -.368
**
 P < 0.01 Significant 
SBP -.702
**
 P < 0.01 Significant 
DBP -.660
**
 P < 0.01 Significant 
WC -.741
**
 P < 0.01 Significant 
WEIGHT -.535
**
 P < 0.01 Significant 
HEIGHT -.013 P > 0.05 not Significant 
BMI -.818
**
 P < 0.01 Significant 
MDA -.875
**
 P < 0.01 Significant 
PON .872
**
 P < 0.01 Significant 
FBS -.783
**
 P < 0.01 Significant 
PPBS -.582
**
 P < 0.01 Significant 
CHOL -.864
**
 P < 0.01 Significant 
TGL -.857
**
 P < 0.01 Significant 
LDL -.912
**
 P < 0.01 Significant 
VLDL -.857
**
 P < 0.01 Significant 
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TABLE 17 
PEARSONS CORRELATION BETWEEN  WAIST     
CIRCUMFERENCE AND OTHER STUDY PARAMETERS 
 
 
 
WC 
CORRELATION 
VALUE 
STATISTICAL 
INFERENCE 
AGE .650
**
 P < 0.01 Significant 
SBP .780
**
 P < 0.01 Significant 
DBP .645
**
 P < 0.01 Significant 
WEIGHT .695
**
 P < 0.01 Significant 
HEIGHT .222 P > 0.05 not Significant 
BMI .870
**
 P < 0.01 Significant 
MDA .915
**
 P < 0.01 Significant 
PON -.907
**
 P < 0.01 Significant 
FBS .734
**
 P < 0.01 Significant 
PPBS .466
**
 P < 0.01 Significant 
CHOL .926
**
 P < 0.01 Significant 
TGL .901
**
 P < 0.01 Significant 
HDL -.741
**
 P < 0.01 Significant 
LDL .906
**
 P < 0.01 Significant 
VLDL .901
**
 P < 0.01 Significant 
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TABLE 18 
PEARSONS CORRELATION BETWEEN 
FBS AND OTHER STUDY PARAMETERS 
 
 
 
FBS 
CORRELATION 
VALUE 
STATISTICAL INFERENCE 
AGE .422
**
 P < 0.01 Significant 
SBP .707
**
 P < 0.01 Significant 
DBP .680
**
 P < 0.01 Significant 
WC .734
**
 P < 0.01 Significant 
WEIGHT .658
**
 P < 0.01 Significant 
HEIGHT .322
*
 P > 0.05  Significant 
BMI .723
**
 P < 0.01 Significant 
MDA .816
**
 P < 0.01 Significant 
PON -.773
**
 P < 0.01 Significant 
PPBS .701
**
 P < 0.01 Significant 
CHOL .764
**
 P < 0.01 Significant 
TGL .759
**
 P < 0.01 Significant 
HDL -.783
**
 P < 0.01 Significant 
LDL .783
**
 P < 0.01 Significant 
VLDL .759
**
 P < 0.01 Significant 
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TABLE 19 
PEARSONS CORRELATION BETWEEN 
SBP AND OTHER STUDY PARAMETERS 
 
SBP 
CORRELATION 
VALUE 
STATISTICAL INFERENCE 
AGE .643
**
 P < 0.01 Significant 
DBP .837
**
 P < 0.01 Significant 
WC .780
**
 P < 0.01 Significant 
WEIGHT .654
**
 P < 0.01 Significant 
HEIGHT .069 P > 0.05 not Significant 
BMI .638
**
 P < 0.01 Significant 
MDA .728
**
 P < 0.01 Significant 
PON -.650
**
 P < 0.01 Significant 
FBS .707
**
 P < 0.01 Significant 
PPBS .436
**
 P < 0.01 Significant 
CHOL .711
**
 P < 0.01 Significant 
TGL .702
**
 P < 0.01 Significant 
HDL -.702
**
 P < 0.01 Significant 
LDL .723
**
 P < 0.01 Significant 
VLDL .702
**
 P < 0.01 Significant 
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TABLE 20 
PEARSONS CORRELATION BETWEEN 
DBP AND OTHER STUDY PARAMETERS 
 
DBP 
CORRELATION 
VALUE 
STATISTICAL INFERENCE 
AGE .471
**
 P < 0.01 Significant 
SBP .745
**
 P < 0.01 Significant 
WC .645
**
 P < 0.01 Significant 
WEIGHT .530
**
 P < 0.01 Significant 
HEIGHT .206 P > 0.05 not Significant 
BMI .635
**
 P < 0.01 Significant 
MDA .722
**
 P < 0.01 Significant 
PON -.663
**
 P < 0.01 Significant 
FBS .680
**
 P < 0.01 Significant 
PPBS .511
**
 P < 0.01 Significant 
CHOL .696
**
 P < 0.01 Significant 
TGL .696
**
 P < 0.01 Significant 
HDL -.660
**
 P < 0.01 Significant 
LDL .700
**
 P < 0.01 Significant 
VLDL .696
**
 P < 0.01 Significant 
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TABLE 21 
MEAN PARAOXONASE& MDA LEVELS STRATIFIED BY THE 
NUMBER OF COMPONENTS OF METABOLIC SYNDROME 
MEAN 
PON-1 
NO OF PERSONS      
SATISFYING CRITERIA 
NO OF 
CRITERIA 
SATISFIED 
MEAN MDA 
81.28 13 3 5.828 
65.71 12 4 6.153 
45.10 25 5 9.203 
 
BARCHART    11 
MEAN PARAOXONASE&  MDA LEVELS STRATIFIED BY THE 
NUMBER OF  COMPONENTS OF METABOLIC SYNDROME 
 
 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
PON MDA PON MDA PON MDA 
3 4 5 
81.28 
5.828 
65.71 
7.213 
45.1 
9.203 
112 
 
RESULTS AND STATISTICAL ANALYSIS 
A total of 100 subjects were included in the present study. Out of 
this 100, 50 were under the study group (Metabolic Syndrome) and the 
other 50 were under the control group (healthy individuals).25 Male and 25 
female subjects in control and study group in the age group of 21-60 years 
were included in this study. 
The serum PON1 activity and the levels of  Malondialdehyde ,blood 
glucose , total cholesterol, triglycerides, HDL, blood urea and serum 
creatinine were estimated,   for all the samples collected for the study. 
VLDL and LDL values were calculated Anthropometric Measurements & 
BP were measured & BMI were calculated .The values obtained in both the 
control and study groups are presented in the master chart I and II. 
Table 1  shows descriptive statistics of control& study groups which 
include the mean values of Age, Anthropometric Data,BP,Serum 
PON,MDA, Blood Sugars &Lipid Parameters. 
Table 2  shows Age & Sex distribution in Study & Control groups.40% of 
the Control group is between 21-40 yrs of age.38% of the Study group is 
between 21-40 yrs of age. 60% of the Control group is between 41-60 yrs 
of age. 62% of the Study group is between 41-60  yrs of age. 
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Table 3 shows that mean serum PON1 activity in  Study group  (59.32 19 
U/L)  is lower than the control group  (154.84 30.71 U/L). There is a 
highly significant difference between the two groups.(p=<0.0001). 
Table 4 shows that mean Serum Malondialdehyde values in study group  
(7.81  3.8 µmol/L) is significantly increased, than that of control group 
(2.8091.40). (P= <0.0001).  
Table 5   
Student’s t- Test analysis of BMI between Control & Study group.  
In this table there is statistical elevation of mean BMI level in study 
group of (32.68  1.88) when compared to mean BMI level in control 
group of .( 23.65  3.58)  which is statistically significant. 
Table 6 
Student’s t- Test analysis of Waist Circumference between Control & 
Study group.  
In this table there is statistical elevation of mean Waist 
Circumference level in study group of (110.26  10.77) when compared to 
mean Waist Circumference level in control group of (89.1  7.62) which is 
statistically significant. 
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Table 7 
  Student’s t- Test analysis of Fasting Blood Glucose between Control 
& Study group.  
            In this table there is statistical elevation of mean Fasting Blood 
Glucose level in study group of (107.36 8.80) when compared to mean 
Fasting Blood Glucose level in control group of ( 91.686.00   ) which is 
statistically significant. 
Table 8 
Student’s t- Test analysis of Systolic & Diastolic BP between 
Control & Study group.  
In this table, there is statistical elevation of mean Systolic BP(133.18 
±7.575&,Diastolic BP(84.76 ±4.118) of study group ,with the mean values 
of Systolic BP(125.84 ±6.65 ),Diastolic BP(80.14 ±  2.40) of control group 
. 
Table 9 
  Student’s t- Test analysis of  Triglycerides between Control & Study 
group.  
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      In this table there is statistical elevation of mean Triglycerides level in 
study group of (161.54 22.11) when compared to mean Triglycerides 
level in control group of (115.12  18.02) which is statistically significant. 
Table 10 
  Student’s t- Test analysis of  lipid profile between Control & Study 
group.  
This table shows statistical elevation between mean values of Total 
cholesterol (198.64  20.63), Triglycerides (161.54 22.11), LDL (130.95 
 20.44) and VLDL (32.30  4.42) of the study group with  the mean 
values of total cholesterol (150.54  19.77),TGL (115.12  18.02), LDL 
(79.156  19.59) and VLDL (23.024  3.6) of the control group  showed a 
significant increase of all the above parameters in the study group. (P= 
<0.0001) . 
Table11 Paraoxonase-1 activity between 3, 4 & 5 components of 
Metabolic Syndrome  is statistically significant. 
Table 12 
  Pearsons correlation between Serum Paraoxonase-1 activity & other 
Parameter. 
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This Table shows PON has positive correlation with HDL which is 
statistically significant, Negative correlation with Age, MDA, BP, WC, 
Weight, BMI, Blood sugar, T.Cholesterol, TGL,VLDL & LDL which is 
statistically significant. 
Table 13 
        Pearsons correlation between Serum MDA level & other Parameters. 
This Table shows MDA has positive correlation with Age, BP, WC, 
weight, BMI, Blood sugar, T.Cholesterol, TGL,VLDL & LDL which is 
statistically significant, Negative correlation with PON & HDL which is 
statistically significant. 
Table 14 
        Pearsons correlation between Serum BMI level & other Parameters. 
This Table shows BMI has positive correlation with Age, BP, WC, 
weight, Blood sugar, T.Cholesterol, TGL, VLDL & LDL which is 
statistically significant, Negative correlation with PON & HDL which is 
statistically significant. 
Table 15 
Pearsons correlation between Serum TGL level & other Parameters. 
117 
 
This Table shows TGL has positive correlation with Age, BP, WC, 
weight, BMI, Blood sugar, T.Cholesterol,VLDL & LDL which is 
statistically significant, Negative correlation with PON & HDL which is 
statistically significant. 
Table 16 
        Pearsons correlation between HDL & other Parameters. 
This Table shows HDL has positive correlation with PON-1 Activity 
which is statistically significant,Negative correlation with Age,MDA, BP, 
WC,Weight, BMI, Blood sugar, T.Cholesterol, TGL,VLDL & LDL which 
is statistically significant. 
Table 17 
        Pearsons correlation between Waist Circumference level & other 
Parameters. This Table shows Waist Circumference has positive 
correlation with Age, BP, weight, BMI, Blood sugar, T.Cholesterol, 
TGL,VLDL & LDL which is statistically significant, Negative correlation 
with PON & HDL which is statistically significant. 
Table 18 
        Pearsons correlation between Serum FBS level & other Parameters. 
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This Table shows MDA has positive correlation with Age, BP, WC, 
weight, BMI, T.Cholesterol,TGL,VLDL&LDL which is statistically 
significant, Negative correlation with PON & HDL which is statistically 
significant.  
Table 19 
        Pearsons correlation between Systolic BP& other Parameters. 
  This Table shows Systolic BP has positive correlation with Age,  
WC, weight, BMI, Blood sugar, T.Cholesterol, TGL,VLDL & LDL which 
is statistically significant, Negative correlation with PON & HDL which is 
statistically significant. 
Table  20 
        Pearsons correlation between Diastolic Bp& other Parameters. 
This Table shows MDA has positive correlation with Age, WC, 
weight, BMI, Blood sugar, T.Cholesterol, TGL,VLDL & LDL which is 
statistically significant, Negative correlation with PON & HDL which is 
statistically significant. 
Table 21  
This table shows mean PON1 activity level and Malondialdehyde level 
stratified by the no of components of metabolic syndrome. 
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 At the Mean PON level of 81.28 U/L & Mean Malondialdehyde 
level of 5.22 µmol/L –three components of metabolic syndrome 
satisfied. 
  At the Mean PON level of 65.71U/L & Mean Malondialdehyde 
level of 6.15 µmol/L –Four components of Metabolic syndrome 
satisfied.  
 At the Mean PON level of 45.10 U/L & Mean Malondialdehyde 
level of 9.203 µmol/L –three components of Metabolic syndrome 
satisfied. 
Scatter plot Diagram to show correlation between PON-1 activity 
&Malondialdehyde level. As the PON 1 activity level decreases MDA 
levels increases.                
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DISCUSSION 
The incidence and impact of the Metabolic Syndrome have risen to 
alarming proportions and there is a great need for therapeutic and 
preventive measures against this major health problem. Atherosclerotic 
macrovascular complication (especially coronary artery disease) is the 
leading cause of morbidity and mortality in Metabolic syndrome.
101 
Dyslipidemia in Metabolic Syndrome constitutes an important 
determinant of atherosclerosis.
102
 HDL is one of the important, 
independant protective factor for atherosclerosis. Paraoxonase-1(PON-1) is 
an enzyme that confers the antiatherogenic and antioxidant properties to 
HDL. PON-1 is an HDL associated antioxidant enzyme, which diminishes 
the LDL oxidation and prevents the proinflammatory response elicited by 
oxidised LDL, by hydrolysing the lipid peroxides.
103,104
 Moreover PON-1 
is critical, for preventing the oxidation of HDL, allowing it to maintain its 
function. Thus PON-1 activity is responsible for the antiatherogenic 
property of HDL.
105 
 Reduction in PON-1 activity occurs in Metabolic Syndrome and it 
may be due to,  
1. Increased endogenous circulating inhibitors like lipid peroxidation 
products. 
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2. Increased TNF-α in Mets leads to decreased ATP Binding Cassette 
Protein and decreases ABC-G1.it also decreases Apo-A1 & Apo-
A1V expression all these decline in HDL levels leads to decreased 
PON-1 activity. 
3. Increased leptin levels in Mets leads to increased generation of free 
radicals and it directly inhibit Paraoxonase activity. 
4. Increased cytokines and acute phase proteins in Mets causes reduced 
PON-1 enzyme activity. 
            By measuring the PON-1 activity in Metabolic Syndrome, we can 
predict the atherosclerosis earlier, and it may help for taking early 
preventive measures against cardiovascular disease.
106 
The present study done with 100 subjects ( 50 were Metabolic 
Syndrome individuals and 50 were healthy subjects) supports the fact that 
the measurement of PON-1 activity is useful in predicting the risk of 
cardiovascular disease in Metabolic Syndrome. 
Comparison of mean value of the serum PON-1 activity in the study 
group (59.32 19 U/L) with that of the control group (154.84 30.71 U/L) 
showed a significant fall in the study group (P= <0.0001). This study also 
supports the fact that there is a significant decrease in PON-1 activity in 
Metabolic Syndrome 
85,88.
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Analysis of Serum Malondialdehyde shows, that the mean 
Malondialdehyde values of study group (7.81  3.8 µmol/L)  is 
significantly increased, when compared with  that of control group 
(2.8091.40). (P= <0.0001),thus it shows increased lipid peroxidation in 
Metabolic Syndrome .so,by measuring lipid peroxidation levels 
precautions can be taken by antioxidants to prevent atherosclerosis. 
Analysis of Fasting Blood Glucose shows, that the mean values of 
FBS in study group (107.36 8.80) is significantly increased, than that of 
control group (91.686.00). (P=<0.0001) satisfies one of the component of 
Metabolic Syndrome. 
Analysis of parameters of lipid profile shows, that the mean values 
of HDL in study group (35.38 4.60) is significantly decreased, than that 
of control group (48.36 4.73). (P= <0.001). 
Comparison of mean values of Total cholesterol (198.64  20.63), 
Triglycerides (161.54 22.11), LDL (130.95  20.44) and VLDL (32.30  
4.42) of the study group, with the mean values of total cholesterol (150.54 
 19.77), TGL (115.12  18.02), LDL (79.156  19.59) and VLDL (23.024 
 3.6) of the control group showed a significant increase of all the above 
parameters in the study group. (P= <0.0001) The difference in the level of 
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these parameters, between the two groups are associated with dyslipidemic 
changes, which are the components of Metabolic Syndrome .
 
Comparison of Mean Values of Waist circumference 
(110.26±10.77cms),Weight(88.22±8.23kgs),BMI(32.68±1.88),Systolic 
BP(133.18±7.575) ,Diastolic BP(84.76±4.118)of study group ,with the 
mean values of Waist circumference (89.1±7.62cms), Weight 
(62.64±10.88kgs),BMI(23.65± 3.58),Systolic BP(125.84±6.65) ,Diastolic 
BP(80.14 ±2.40) of control group showed a significant increase of all the 
above parameters in the study group,(P= <0.0001).Thus this above values 
satisfies the components of Metabolic Syndrome.
 
In the Pearson’s correlation analysis, the PON activity shows highly 
significant negative correlation with  Age, BP, WC, BMI, FBS, and 
TGL.P(<0.001).It shows that  PON Activity decreases with the 
components of metabolic syndrome. Age is the non negligible factor, other 
than Age, remaining could be modifiable with appropriate Exercise, Life 
Style changes,& drugs in order to prevent atherosclerosis.
 
The levels of HDL shows a significant positive correlation with the 
PON activity.P= <0.001 & negative correlation with Malondialdehyde, 
Age, BP, WC, BMI, FBS, and TGL.P (<0.001) this correlation proves the 
association of PON with HDL.
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In the Pearson’s correlation analysis, Serum Malondialdehyde levels 
shows highly significant Positive correlation with  Age, BP, WC, BMI, 
FBS, and TGL.P(<0.001).It shows that Malondialdehyde levels increases 
with the components of metabolic syndrome. Age is the non negligible 
factor, other than Age, remaining could be modifiable with appropriate 
Exercise, Life Style changes,& drugs in order to prevent Oxidative stress 
and other events related to oxidative stress .
 
At the Mean PON level of 81.28 U/L & Mean Malondialdehyde 
level of 5.22 µmol/L –three components of Metabolic syndrome are 
satisfied. At the Mean PON level of 65.71U/L & Mean Malondialdehyde 
level of 6.15 µmol/L –Four components of Metabolic syndrome are 
satisfied. At the Mean PON level of 45.10 U/L & Mean Malondialdehyde 
level of 9.203 µmol/L –three components of Metabolic syndrome are 
satisfied. 
As the number of components of Metabolic Syndrome increases 
mean PON 1 Activity decreases & mean MDA levels increases.Thus it 
shows increases in Lipid Peroxidation with decreased in PON activity. 
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                                         CONCLUSION
 
This study shows that there is a significant decrease in PON-1 
activity in Metabolic Syndrome group and there is significant increase in 
Malondialdehyde .Since PON-1 is an antiatherogenic and antioxidant 
enzyme, associated with HDL, reduction in PON-1 activity in Metabolic 
Syndrome, may play an important role in causation of premature 
atherosclerosis.
107,108 
Based on the results obtained the present study shows that PON-1 
activity may be used as a marker for early prediction of atherosclerosis in 
Metabolic Syndrome. By predicting earlier, early interventional measures 
by pharmaceutical means or by dietary means can be done.
69,73,98,99
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LIMITATIONS OF THE STUDY 
 
1)  HOMA-IR index could have been measured for these 
individuals. 
2) Studies on gene polymorphism would have helped to evaluate 
the discordance in human PON-1 gene between phenotypes 
and genotypes in Metabolic Syndrome. 
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SCOPE FOR FURTHER STUDY 
The intake of nutritional antioxidants such as carotenoids (lycopene 
and beta carotene), vitamin C, and polyphenols (in tea, red wine, grapes, 
licourice root, and pomegranate) by atherosclerotic animals, leads to 
reduction of oxidative stress and to the attenuation of atherosclerosis 
development. This could be related to increase in HDL –PON -1 activity 
through effects on gene expression, or preventing enzyme inactivation and 
on increasing PON-1 stability through it’s binding to HDL.65,69,73,109, 110 
Studies on dietary determinants of serum PON activity in human 
beings can be done in future, so that timely intervention can be done to 
prevent atherosclerosis. 
It has been discovered recently that orally administered short peptide 
sequences resembling the amphipathic helices of Apo A-1, when 
synthesized from D-amino acids (to avoid gastric proteolysis) will be 
active in preventing atherosclerosis in animal models. One of these D-4F 
administered orally to apo–E null mice, decreased atherosclerosis and also 
decreased circulating lipid hydro peroxides and increased pre –β HDL and 
PON activity.Addition of D-4F directly to human plasma also decreased 
lipid peroxides and increased the PON activity .
111 
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                In future, to increase the antioxidative activity of HDL, an 
approach to increase the concentration of selective HDL component such 
as PON -1 by somatic gene transfer may prove beneficial.
111
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 A STUDY OF SERUM PARAOXONASE-1 ACTIVITY IN  
PATIENTS WITH METABOLIC SYNDROME 
PROFORMA 
NAME OF THE PATIENT : 
 
AGE    : 
 
OCCUPATION  : 
 
ADDRESS   : 
 
COMPLAINTS  : 
 
PAST HISTORY  : 
 
PERSONAL HISTORY : 
 
FAMILY HISTORY  : 
 
DRUG HISTORY  : 
GENERAL EXAMINATION:          
                                               Ht:                Wt:            BMI:               BP:                 PR: 
 
SYSTEMIC EXAMINATION:      
                                            CVS:                                                   RS:                                                           
                                            ABD:                                                  CNS:                                                                                     
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INVESTIGATIONS : 
1. BLOOD SUGAR :       FBS:                               PPBS: 
 
2. SERUM PARAOXONASE: 
 
3. SERUM MAlONDIALDEHYDE 
 
4. BLOOD UREA: 
 
5.SERUM CREATININE: 
 
6.LIPID PROFILE: 
 
TOTAL CHOLESTEROL: 
 
TRIGLYCERIDES: 
 
HDL: 
 
LDL: 
 
VLDL: 
 
 
 
 
 
149 
 
 
CONSENT FORM 
 
 
Dr.T.Rajalakshmi post graduate student in the department of Biochemistry, 
Thanjavur medical college, Thanjavur is doing a Study on Serum 
Paraoxonase -1 Activity in Patients with Metabolic Syndrome. The 
procedure has been explained to me clearly. I understand that there are no 
risks involved in the above procedures. I hereby give my consent to 
participate in this study. The data obtained here may be used for research 
and publication. 
 
Signature : 
 
Name: 
 
Place:  
 
 
 
